Involvement of CytochromeP4504a in Adenosine A1 receptor mediated regulation of vascular tone

Swati S Kunduri
West Virginia University

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Kunduri, Swati S, "Involvement of CytochromeP4504a in Adenosine A1 receptor mediated regulation of vascular tone" (2013). Graduate Theses, Dissertations, and Problem Reports. 3655.
https://researchrepository.wvu.edu/etd/3655

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact researchrepository@mail.wvu.edu.
Involvement of CytochromeP4504a in Adenosine A1 receptor mediated regulation of vascular tone

Swati S Kunduri

Dissertation submitted to the School of Pharmacy at West Virginia University in partial fulfillment of the requirements for the degree of

Doctor of Philosophy

in

Pharmaceutical and Pharmacological Sciences

S. Jamal Mustafa, Ph. D., Chair
Matthew Boegehold, Ph. D.
Robert Brock, Ph. D.
Gregory Dick, Ph. D.
Jason Huber, Ph. D.
Mohammed Nayeem, Ph.D.

Department of Pharmaceutical and Pharmacological Sciences

Morgantown, West Virginia
2013

Keywords: Vascular tone; Adenosine; A1 adenosine receptors; Cyp4a; BK channels; PKC-α; ERK
Copyright 2013 Swati S Kunduri
ABSTRACT

Involvement of CypP4504a in Adenosine A1 receptor mediated regulation of vascular tone

Swati S Kunduri

Cardiovascular diseases are one of the leading causes of morbidity and mortality worldwide. The regulation of vascular tone plays an important role in normal cardiovascular function. Adenosine, an autacoid has several physiological and pathophysiological roles, apart from the regulation of vascular tone. Adenosine receptor (AR) contracts and relaxes blood vessels through all four subtypes (A1, A2A, A2B, and A3) linked to different signaling mechanisms. Deciphering complex tissue responses remains difficult because relationships of individual receptor subtypes and various end-effectors (e.g., ion channels) are yet to be identified. Apart from adenosine, 20-HETE, a cytochrome P4504a (Cyp4a) metabolite of arachidonic acid (AA) is a potent vasoconstrictor.

We hypothesized that A1AR induced contraction of the smooth muscle involves Cyp4a, with Protein Kinase C (PKC)-α, extracellular regulated kinase (ERK) 1/2 contributing to the downstream signaling events. Another key question we addressed were the ion channel(s) contributing to smooth muscle contraction. Experiments included isometric tension recordings of aortic contraction and western blots. In addition, patch clamp experiments were done with freshly isolated smooth muscle cells from wild type (WT) and A1 knockout (A1KO) mice aortae. We found that inhibition of Cyp4a led to lesser contraction in the adenosine agonists’ mediated responses. 20-HETE induced contraction in both WT and A1KO, but this response was lower in A1KO. Inhibition of PKC-α and ERK1/2 attenuated the 20-HETE-induced contraction in both WT and A1KO. These findings suggest that A1AR couples with 20-HETE and negatively modulates vascular tone through PKC-α and ERK1/2. Furthermore, electrophysiological experiments revealed that non-selective adenosine agonist increased the BK current in A1KO as compared to the WT. This suggests A1 receptors have a negative regulatory effect on BK current. On the other hand, A1 selective agonist decreased the BK current in WT, with no effect on A1KO. PKC-α inhibitor abolished the effect of the A1 selective agonist on BK current. These findings suggest that A1AR regulates contraction of the aortic smooth muscle through inhibition of BK channels in a PKC-α dependent manner. From these data, we conclude that A1AR negatively couples with 20-HETE and by inhibiting BK channels mediates smooth muscle contraction via PKC-α.
Dedicated to my mother and father, Sailaja and Iswara Dutt and sister Shruti and
husband, Kamalesh
Acknowledgement

First and foremost, I thank GOD for giving me the strength and grace to come 13000 miles away from my family to pursue my studies.

This dissertation would not have been completed had it not been for the many people who contributed to it. I would like to thank my mentor, Dr. S. Jamal Mustafa for giving me an opportunity in his lab and for his continuous guidance, patience and mentorship during these four and half years. I am very grateful to him for encouraging me to stretch beyond my comfort zone and help me discover my abilities more. A special thanks to Dr. Nayeem, co-investigator on the grant for his valuable input and support. I am thankful to my committee members: Drs. Matt Boegehold, Rob Brock, Jason Huber for their guidance during the course of my dissertation. My deepest gratitude to our collaborator and committee member, Dr. Gregory Dick for graciously mentoring me in patch clamp technique. His kindness and ever willingness to help and answer questions has shaped my project a lot. I would also like to thank our collaborator Dr. Samuel Poloyac at University of Pittsburgh and Dr. Stephen Tilley at University of North Carolina.

I have had the opportunity to work with some wonderful people during these years in Dr. Mustafa’s lab. Each one of them has taught me something and helped me out at various points. Thank you: Drs. Teng, Nadeem and; especially Dr. Ponnoth, a very dear friend, always willing to help and give her best suggestions; Dr. Sharifi and fellow student Isha, who have been very supportive friends; our lab technicians, past and present, Brandy Wilmoth and Sherry Xie. A special thanks to the new members in our lab in the past one year Dr. Zhou and fellow student Ahmad Hanif for their support and
encouragement. I am also thankful to Claire Noel, Debbie Beery, Teresa Lewis, Vickie White, Brenda Moran and Brad Rager. I would like to acknowledge the staff and students of Departments of Basic Pharmaceutical Sciences, Physiology and Pharmacology and Center for Cardiovascular and Respiratory Sciences. Thanks to Drew Fancher and Dr. Asano in the Dr. Dick’s lab for all their tips during the patch clamp experiments.

I am very grateful to Dr. Nidhi Malhotra who has been there with me right from the time I applied for graduate programs. I also express my gratitude to Kimberly Miede Arnold, Praveena Jayaraman, Dr. Brandi Snyder and senior graduate students: Drs. Sanjeev Kumar, Neelam Azad and Anand Iyer.

Last but certainly not the least, I thank my family: my mother whose has been the driving force and without whom I would have never completed this; my father for being constant source of encouragement and support; my husband for his unconditional support, love, patience and sacrifice during these years of long distance marriage and encouragement during the tough times and helping me realize my strengths and my sister who has been my biggest fan and critic has helped me immensely. I thank my extended family in this country and back in India who have always been my strength and support system.
Table of Contents
ABSTRACT ................................................................................................................................................................... ii
LIST OF FIGURES .................................................................................................................................................. viii
LIST OF ABBREVIATIONS .................................................................................................................................... ix
1. CHAPTER ONE: INTRODUCTION ........................................................................................................................ 1
   Generation of adenosine and its metabolism ........................................................................................... 1
   Vascular tone ......................................................................................................................................................... 3
   Adenosine Receptors .......................................................................................................................................... 3
   Role of A₁ AR in regulation of vascular tone ............................................................................................. 5
   Arachidonic acid metabolites ......................................................................................................................... 7
   EETs in the regulation of vascular tone ........................................................................................................ 10
   20-HETE in the regulation of vascular tone ............................................................................................ 11
   Adenosine and Cyp450 metabolites in the regulation of vascular tone ............................................ 12
   Potassium (K⁺) channels in the regulation of vascular tone ...................................................................... 12
   BK channels in the regulation of vascular tone ....................................................................................... 14
   Adenosine and BK channels ......................................................................................................................... 17
   Specific Aims ....................................................................................................................................................... 19
   References ........................................................................................................................................................... 21
2. CHAPTER TWO: ADENOSINE A₁ RECEPTORS LINK TO SMOOTH MUSCLE CONTRACTION VIA CYP4A, PKC-α AND ERK1/2 ................................................................................................................................. 38
   Abstract ................................................................................................................................................................. 38
   Introduction ........................................................................................................................................................ 40
   Methods ............................................................................................................................................................ 42
   Real Time PCR ................................................................................................................................................ 45
   Results ............................................................................................................................................................... 47
   Role of PKC-α in 20-HETE-induced contraction .................................................................................. 49
   Role of ERK1/2 kinase in 20-HETE-induced contraction ................................................................. 49
   Discussion ............................................................................................................................................................ 58
   References ........................................................................................................................................................... 63
3. CHAPTER THREE: ADENOSINE A₁ RECEPTORS INHIBIT BK CHANNELS THROUGH PKC-α DEPENDENT MECHANISM IN MOUSE AORTIC SMOOTH MUSCLE CONTRACTION ........................................ 69
   Abstract ................................................................................................................................................................. 69
   Introduction ........................................................................................................................................................ 70
Materials and Methods ................................................................................................................................. 72
Animals .............................................................................................................................................................. 72
Electrophysiology ............................................................................................................................................... 74
Real Time PCR .................................................................................................................................................. 75
Statistics ............................................................................................................................................................ 75
Results ............................................................................................................................................................... 77
Total BK current and BK subunit expression in WT and A1KO mice aortic myocytes ................... 77
Effect of 20-HETE on BK current in WT and A1KO mice aortic myocytes ........................................ 77
Effect of NECA on BK current in WT and A1KO mice aortic myocytes .................................................. 78
Effect of CCPA on BK current in WT and A1KO mice aortic myocytes .................................................. 78
Effect of PKCα inhibition on BK current in WT and A1KO mice aortic myocytes ....................... 79
Discussion ......................................................................................................................................................... 91
Reference ......................................................................................................................................................... 96
4. CHAPTER FOUR: CONCLUSIONS ................................................................................................................. 101
Future Directions ............................................................................................................................................. 109
References ....................................................................................................................................................... 112
PUBLICATIONS and ABSTRACTS .................................................................................................................. 131
APPENDIX A ..................................................................................................................................................... 132
APPENDIX B ..................................................................................................................................................... 135
APPENDIX C ..................................................................................................................................................... 139
CURRICULUM VITAE ....................................................................................................................................... 144
LIST OF FIGURES

Figure 1.1: Structure of Adenosine .............................................................. 2
Figure 1.2: Metabolism of Adenosine (Vallon et al., 2006) ......................... 2
Figure 1.3: Structure of adenosine A1 receptor (Nell and Albrecht-Kupper, 2009) ...... 6
Figure 1.4: The enzymatic pathway of AA producing EETs and HETEs .......... 9
Figure 1.5: Structure of BK channel (Ledoux et al., 2006) ............................ 16
Figure 1.6 ................................................................................................... 16
Figure 2.1: Cyp4a protein and mRNA levels in WT and A1KO. ...................... 50
Figure 2.2: Effect of Adenosine Receptor agonists’ and acetylcholine -induced responses in WT and A1 KO aortae and mesenteric arteries .......................................................... 51
Figure 2.3: Effect of the CYP4a product, 20-HETE on smooth muscle contraction from WT and A1KO mice ...................................................................................... 52
Figure 2.4: 20-HETE formation rate in microsomes from WT and A1KO mouse aortae (n=6-8) ........................................................................................................ 53
Figure 2.5: Role of Cyp2c29 ........................................................................... 54
Figure 2.6: Effect of on PKC-α on WT and A1KO contractile responses to 20-HETE ... 55
Figure 2.7 Effect of ERK ½ on WT and A1KO mouse aortae contractile responses (A) ... 56
Figure 2.8 Adenosine A1 receptors link to smooth muscle contraction via CYP4a, PKC-α, and ERK1/2. .................................................................................................................. 57
Figure 3.1: Whole-cell K+ current and BK channel subunit expression is similar in smooth muscle from WT and A1KO mice. .............................................................. 81
Figure 3.2: Effect of 20-HETE on BK current in WT and A1KO aortic myocytes: .... 82
Figure 3.3: Effect of NECA on BK current in WT and A1KO aortic myocytes .......... 83
Figure 3.4: Effect of CCPA on BK current in WT and A1KO aortic myocytes .......... 84
Figure 3.5: Effect of PKCα inhibitor, Gö6976 on BK current in WT and A1KO aortic myocytes .......................................................................................................................... 85
Figure 3.6 Effect of NS1619 on NECA induced relaxation .............................. 86
Figure 3.7 Effect of Penitrem A (Pen A) on adenosine agonists’ induced responses: (A)Effect of Penitrem A on NECA induced vascular response ................................. 87
Figure 3.8 Effect of Penitrem A (BK channel inhibitor; Pen A) and NS1619 (BK channel opener;NS) on CCPA induced contraction. ............................................................ 88
Figure 3.9 Adenosine receptor expression in WT and A1KO mice aortae (n=10) ....... 89
Figure 3.10: Adenosine A1 receptors regulate aortic smooth muscle contraction by inhibiting BK channels via PKC-α dependent mechanism. ........................................... 90
Figure 4.1: Schematic showing the events leading from activation of A1AR coupled to Cyp4a product, 20-HETE and mediating contraction through PKC-α and p-ERK1/2 and BK channels Figure 4.2: Schematic showing the events in the absence of A1AR. NECA possibly activates A2AR, leading to activation of Cyp-epoxygenases , which produce EETs and activae KATP channels ........................................................................................................ 106
Figure 4.3: Effect of Glibenclamid (Glib; 10µM) on CCPA induced contraction ....... 108
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg</td>
<td>micro gram</td>
</tr>
<tr>
<td>µl</td>
<td>micro liter</td>
</tr>
<tr>
<td>AA</td>
<td>Arachidonic acid</td>
</tr>
<tr>
<td>A₁AR</td>
<td>A₁ adenosine receptor</td>
</tr>
<tr>
<td>A₂AAR</td>
<td>A₂A adenosine receptor</td>
</tr>
<tr>
<td>A₂BAR</td>
<td>A₂B adenosine receptor</td>
</tr>
<tr>
<td>A₃AR</td>
<td>A₃ adenosine receptor</td>
</tr>
<tr>
<td>AC</td>
<td>Adenylyl cyclase</td>
</tr>
<tr>
<td>ACh</td>
<td>Acetylcholine</td>
</tr>
<tr>
<td>ADA</td>
<td>Adenosine deaminase</td>
</tr>
<tr>
<td>ADO</td>
<td>Adenosine</td>
</tr>
<tr>
<td>ADP</td>
<td>Adenosine diphosphate</td>
</tr>
<tr>
<td>AK</td>
<td>Adenosine kinase</td>
</tr>
<tr>
<td>AMP</td>
<td>Adenosine monophosphate</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>AR</td>
<td>Adenosine receptor</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>BK</td>
<td>Large conductance Potassium channels</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>Ca²⁺</td>
<td>Calcium</td>
</tr>
<tr>
<td>cAMP</td>
<td>Cyclic adenosine monophosphate</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>cGMP</td>
<td>Cyclic guanosine monophosphate</td>
</tr>
<tr>
<td>CGS 21860</td>
<td>2-p-(2-carboxyethyl)phenethylamino-5' N-ethylcarboxy amido adenosine hydrochloride</td>
</tr>
<tr>
<td>COX</td>
<td>Cyclooxygenase</td>
</tr>
<tr>
<td>COOH</td>
<td>Carboxy</td>
</tr>
<tr>
<td>CRC</td>
<td>Concentration response curve</td>
</tr>
<tr>
<td>Cyp-epoxygenases</td>
<td>CytochromeP450 epoxygenase</td>
</tr>
<tr>
<td>DAG</td>
<td>Diacylglycerol</td>
</tr>
<tr>
<td>diHETEs</td>
<td>Di hydroxy eicosatrienoic acids</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DPCPX</td>
<td>1,3-Dipropyl-8-cyclopentylxanthine</td>
</tr>
<tr>
<td>EDHF</td>
<td>Endothelium-Derived Hyperpolarizing Factor</td>
</tr>
<tr>
<td>EETs</td>
<td>Epoxyeicosatrienoic acids</td>
</tr>
<tr>
<td>EGTA</td>
<td>Ethylene glycol tetraacetic acid</td>
</tr>
<tr>
<td>ERK1/2</td>
<td>Extracellular signal-regulated kinase 1/2</td>
</tr>
<tr>
<td>Glib</td>
<td>Glibenclamide</td>
</tr>
<tr>
<td>GPCR</td>
<td>G Protein Coupled Receptor</td>
</tr>
<tr>
<td>GTP</td>
<td>Guanosine triphosphate</td>
</tr>
<tr>
<td>HEPES</td>
<td>4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</td>
</tr>
<tr>
<td>HETE</td>
<td>Hydroxy eicosa-trienoic acids</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>HET0016</td>
<td>N-hydroxy-N'-(4-n-butyl-2-methylphenyl)Formamidine</td>
</tr>
<tr>
<td>IP$_3$</td>
<td>Inositol triphosphate</td>
</tr>
<tr>
<td>K$_{ATP}$</td>
<td>ATP-dependent K$^+$ channels</td>
</tr>
<tr>
<td>KCl</td>
<td>Potassium Chloride</td>
</tr>
<tr>
<td>kg</td>
<td>Kilogram</td>
</tr>
<tr>
<td>Kir</td>
<td>inward rectifier K$^+$ channels</td>
</tr>
<tr>
<td>KO</td>
<td>Knock out</td>
</tr>
<tr>
<td>K$_V$</td>
<td>voltage-dependent K$^+$ channels</td>
</tr>
<tr>
<td>LOX</td>
<td>Lipoygenase</td>
</tr>
<tr>
<td>LT</td>
<td>Leukotrienes</td>
</tr>
<tr>
<td>L-VDCC</td>
<td>L-type voltage dependent Ca$^{2+}$ channel</td>
</tr>
<tr>
<td>MAPK</td>
<td>mitogen-activated protein kinase</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>MLCK</td>
<td>Myosin light chain kinase</td>
</tr>
<tr>
<td>ml</td>
<td>milliliter</td>
</tr>
<tr>
<td>mm</td>
<td>millimeter</td>
</tr>
<tr>
<td>mM</td>
<td>millimole</td>
</tr>
<tr>
<td>NADPH</td>
<td>Nicotinamide adenosine dinucleotide phosphate</td>
</tr>
<tr>
<td>Nox-2</td>
<td>NADPH oxidase-2</td>
</tr>
<tr>
<td>NE</td>
<td>Norepinephrine</td>
</tr>
<tr>
<td>NECA</td>
<td>N-ethylcarboxamide-adenosine</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>NH₂</td>
<td>Amino terminus</td>
</tr>
<tr>
<td>NO</td>
<td>Nitric oxide</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PE</td>
<td>Phenylephrine</td>
</tr>
<tr>
<td>PG</td>
<td>Prostaglandin</td>
</tr>
<tr>
<td>Pin</td>
<td>Pinacidil</td>
</tr>
<tr>
<td>PKA</td>
<td>Protein kinase A</td>
</tr>
<tr>
<td>PKC</td>
<td>Protein kinase C</td>
</tr>
<tr>
<td>PLC</td>
<td>Phospholipase C</td>
</tr>
<tr>
<td>PPAR-α</td>
<td>Peroxisome proliferator activated receptor</td>
</tr>
<tr>
<td>RyR</td>
<td>Ryanodine receptors</td>
</tr>
<tr>
<td>RCK</td>
<td>Regulator for conductance of K⁺</td>
</tr>
<tr>
<td>RIPA</td>
<td>Radio-immuno precipitation assay</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive oxygen species</td>
</tr>
<tr>
<td>SAH</td>
<td>S-Adenosyl-L-homocysteine</td>
</tr>
<tr>
<td>SAH-hydrolase</td>
<td>S-Adenosyl-L-homocysteine-hydrolase</td>
</tr>
<tr>
<td>SAM</td>
<td>S-Adenosyl-L methionine</td>
</tr>
<tr>
<td>SCH58261</td>
<td>2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine</td>
</tr>
<tr>
<td>SEH</td>
<td>Soluble Epoxide Hydrolase</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>TP</td>
<td>Thromboxane</td>
</tr>
<tr>
<td>TRP</td>
<td>Transient receptor potential</td>
</tr>
<tr>
<td>TRPV4</td>
<td>Vanilloid type 4 TRP</td>
</tr>
<tr>
<td>UPLC</td>
<td>Ultra performance liquid</td>
</tr>
<tr>
<td></td>
<td>chromatography</td>
</tr>
<tr>
<td>VSMC</td>
<td>Vascular smooth muscle cell</td>
</tr>
<tr>
<td>WT</td>
<td>Wild type</td>
</tr>
</tbody>
</table>
CHAPTER ONE: INTRODUCTION

Adenosine, the breakdown product of the energy molecule adenosine triphosphate (ATP), is a ubiquitous nucleoside. In mammalian cells it plays a key role in a number of physiological and pathophysiological conditions. Figure 1.1 shows the chemical structure of Adenosine. Under physiological conditions, some of its regulatory activities include decreasing the glomerular filtration, neuro-modulation during the sleep-wake cycle, anti-inflammatory action, effects on the heart including chronotropy, ionotropy and the regulation of the vascular tone (Fredholm, 2007).

**Generation of adenosine and its metabolism**

Adenosine is released when the cells are metabolically stressed either through an equilibrative transporter on the cell or as a result of cell damage (Abbracchio et al., 2003). At intracellular and extracellular sites, adenosine can be formed by enzymatic hydrolysis from two different substrates. The first pathway, 5′ nucleotidase hydrolyzes adenosine monophosphate (AMP) to adenosine (Frick and Lowenstein, 1976; Newby et al., 1985). Adenosine can also be synthesized by the action of S-adenosylhomocysteine hydrolase (SAH) on S-adenosylhomocysteine (Schutz et al., 1981). SAH is tightly bound to adenosine and prevents its breakdown by adenosine deaminase (ADA) to inosine and the latter is finally broken down to uric acid and excreted in the urine (Lloyd and Fredholm, 1995). In another pathway, adenosine is re-converted to AMP by adenosine kinase (AK). In addition to being metabolized, adenosine uptake into cells occurs by either a carrier system or a sodium-ribonucleoside co-transport system. Once adenosine enters the cell, it binds to its receptors and exerts various physiological effects.
Figure 1.1: Structure of Adenosine

Figure 1.2: Metabolism of Adenosine (Vallon et al., 2006)
**Vascular tone**

The contractile state of the smooth muscle cell is defined as the vascular tone. The smooth muscle of the blood vessel exists in a partial contracted state; this tone increases as the diameter of the vessel decreases. This tone is independent of any hormonal or neural influences as there are sufficient calcium (Ca$^{2+}$) channels on the membrane to maintain the partial contracted state. In addition, the norepinephrine (NE) released from sympathetic fibers further augments the vascular tone (Sherwood Lauralee, Human Physiology Cells to Systems, 7e; (Jackson, 2000).

However, the vascular tone can be regulated by a complex interplay of contracting and relaxing factors, hormones, neurotransmitters, and endothelium-derived hyperpolarizing factors (EDHF). The contraction and relaxation of the smooth muscle is determined by the movement of ions through the ion channels on the plasma membrane.

The role of various contracting and dilating factors and ion channels with focus on adenosine and large conductance potassium (BK) channels in the regulation of vascular tone has been discussed in subsequent sections.

**Adenosine Receptors**

Adenosine exerts its physiological effects by binding to one of its four G-protein coupled receptors: A$_1$, A$_{2A}$, A$_{2B}$ and A$_3$. These glycoproteins have in common a central core of seven transmembrane spanning domains, and each transmembrane is composed of 20-27 amino acids and with 3 extracellular and intracellular loops (Fredholm, 2007). The intracellular loops, extracellular amino (NH$_2$) and the intracellular carboxy (COOH) termini differ in their length, function and sequence variation and are responsible for the specific properties of these receptor proteins. Apart from A$_{2A}$R, all other receptors have cysteine residue in the COOH terminus for receptor palmitoylation. All the ARs are
glycosylated on their second extracellular loop (Moro et al., 2006). Each of these receptors has their own pharmacological profile, affinity to adenosine, tissue distribution and effector coupling. The receptors derive their name due to their affinity to adenosine, which acts as a full agonist at all the four receptors (Fredholm et al., 2001). Adenosine receptors are classified based on their ability to activate or inhibit adenylyl cyclase (AC) and regulation of the cyclic adenosine monophosphate (cAMP) levels.

**A₁ adenosine receptor (A₁AR):** It inhibits AC through inhibition of pertussis toxin sensitive G<sub>i</sub> proteins and decreases the cAMP levels and results in an increased activity of phospholipase C (PLC) activity (Rogel et al., 2005; Tawfik et al., 2005). In cardiac muscle and neurons, A₁ receptor can activate potassium channels (K<sup>+</sup>) and inhibits Q-, P- and N-type Ca<sup>2+</sup> channels (Fredholm et al., 2001). A₁ couples with K<sup>+</sup> channels and is responsible for the bradycardiac effect of adenosine on heart function.

**A₂ adenosine receptor (A₂AR and A₂BR):** It stimulates the AC and increases the cAMP levels through the cholera toxin sensitive G<sub>S</sub> protein in the peripheral system and in the striatal system A₂AR mediates effects through G<sub>olf</sub>. It has anti-inflammatory and vasodilatory role through the activation of PLC. The A₂B receptor signals through G<sub>olf</sub>/q and its activation can either result in increased cAMP or inositol,1,4,5- triphosphate (IP<sub>3</sub>)/ diacylglycerol (DAG) and Ca<sup>2+</sup> levels. Our lab has shown previously that A₂B mediates relaxation in mouse aorta through nitric oxide (NO) in the endothelium (Ansari et al., 2007a)

**A₃ adenosine receptor:** A₃ receptors are negatively coupled to AC and decrease cAMP levels. They also stimulate PLC pathway and aid in mobilizing Ca<sup>2+</sup> (Jacobson and Gao, 2006). In cardiac cells, they provide protection through ATP sensitive K<sup>+</sup> (K<sub>ATP</sub>) channel activation (Tracey et al., 1998). A₃ mediates vasoconstriction through the endothelial
dependent cyclooxygenase (COX) pathway and involves nicotinamide adenosine dinucleotide phosphate (NADPH) oxidase (Nox-2) (Ansari et al., 2007b; El-Awady et al., 2011).

The current thesis focuses on the role of A₁AR in vascular tone regulation.

Role of A₁AR in regulation of vascular tone

A₁AR is a 36 kDa protein found in highest density in the kidney, atria and in lower density in ventricles, lung, pancreas, liver and gastrointestinal tract (GI). The third intracellular loop and the COOH terminus of the receptor influence the coupling of A₁AR to Gᵢ (Tucker et al., 2000). Furthermore, the coupling of the A₁AR is affected by the composition, prenylation state and phosphorylation state of G protein γ subunits (Yasuda et al., 1996; Yasuda et al., 1998). The cytoplasmic domain of the receptor has several serine and threonine residues, which are potential sites for protein kinase A (PKA), protein kinase C (PKC) and β-adrenoreceptor kinase-mediated phosphorylation and may play a role in receptor desensitization (Nell and Albrecht-Kupper, 2009). It is well accepted that adenosine mediates contraction of the smooth muscle in several vascular beds. Activation of adenosine A₁ receptors induces contraction through a COX dependent pathway in pulmonary artery (Biaggioni et al., 1989). Similar results were seen in guinea pig and feline pulmonary vasculature (Szentmiklosi et al., 1995; Cheng et al., 1996). A₁AR activation leads to IP₃ in rabbit airway smooth muscle and negatively modulates the vascular tone (Abebe and Mustafa, 1998). Adenosine at low concentrations contracts the afferent arterioles through A₁AR activation. However at higher concentrations, adenosine has been shown to mediate vasodilation of the afferent arterioles through A₂A, which is coupled to K_ATP channel (Tabrizchi and Bedi, 2001).
Figure 1.1: Structure of adenosine A1 receptor (Nell and Albrecht-Kupper, 2009)
Our lab provided the first evidence that A₁AR negatively modulates the effect of adenosine on vascular tone in mouse aorta and coronary flow regulations (Tawfik et al., 2005) resulting from activation of PLC pathway and Ca^{2+} mobilization (Tawfik et al., 2005). Others have showed similar results in different vascular beds like human cultured prostatic stromal cells (Preston et al., 2004), cat esophageal smooth muscle cells (Shim et al., 2002), guinea pig aorta (Ford and Broadley, 1999) and mouse coronary artery cells, heart, aorta and carotid artery (Prentice et al., 2002; Talukder et al., 2002; Ansari et al., 2009). Though A₁ is primarily known to mediate contraction, there are a few reports suggesting that A₁ mediates vasodilation through K_{ATP} channel in the rat aortic endothelium (Ray and Marshall, 2006), in rat diaphragmatic arterioles (Danialou et al., 1997), in the rat skeletal muscle (Bryan and Marshall, 1999), in pig coronary artery smooth muscle cells (Dart and Standen, 1993).

**Arachidonic acid metabolites**

A major component of the cell membrane phospholipid pool is the arachidonic acid (AA). This 20-carbon fatty acid when released from the membrane is catalyzed by several enzymes to numerous biological metabolites called eicosanoids. Apart from adenosine, AA metabolites can also regulate the vascular tone. It has long been known that AA can be metabolized by COX and lipoxygenases (LOX) to prostaglandins (PG), thromboxane (TP), leukotrienes (LT), 5-, 12- and 15- hydroxyeicosatetraenoic acid (HETE). These metabolites play a significant role in pulmonary and renal function, vascular tone, and inflammation (Roman, 2002; Miyata and Roman, 2005). Cytochrome P450 enzymes metabolize AA, it was discovered thirty years ago (Chacos et al., 1982) and consists of two families: a) Cytochrome P-450-epoxygenases (Cyp epoxygenases) and b) ω-hydroxylases. Cyp epoxygenases catalyzes AA to epoxygenosatrienoic acids
(EETs) and dihydroxyeicosatrienoic acids (diHETEs), while ω-hydroxylases metabolizes them to 19- and 20- HETEs and 7-, 10-, 12-, 13-, 15-, 16-, 17- and 18-HETEs from AA. These metabolites play a pivotal role as second messengers and paracrine factors in liver, kidney, blood vessels, lung, intestines, heart, pancreas and white blood cells and regulate pulmonary, renal, cardiac and vascular function and modulate inflammatory and growth responses (Capdevila et al., 1982; Randriamboavonjy et al., 2005).
Figure 1.2: The enzymatic pathway of AA producing EETs and HETEs
EETs in the regulation of vascular tone

Cyp epoxygenases produce EETs and belong to a conserved super-family of genes with a common evolutionary origin. Epoxygenase enzymes are present in the endothelial and vascular smooth muscle cells. Cyp2C and Cyp2J belonging to the Cyp epoxygenases family convert AA to 5,6-EET; 8,9-EET; 11,12- EET and 14,15-EET. The major CYP epoxygenases in humans are Cyp2C8, Cyp2C9 and Cyp2J2; in rats are Cyp2C11, Cyp2C23 and Cyp2J3; in mice are Cyp2C40, Cyp2C44, Cyp2C29, Cyp2J5 (Fleming, 2001; Michaelis and Fleming, 2006).

Studies in coronary, renal and cerebral vascular beds have shown that EETs increase the organ blood flow or cause vasodilation. Rodents, rabbits, canine and bovine blood vessels have also shown EET vasodilation (Imig et al., 2000; Fleming, 2001; Sudhahar et al., 2010). However, there are also studies showing where 5,6 EET and 8,9-EET mediate vasoconstriction as these metabolites are also substrates for COX enzymes and bind to the TP receptors, activating it (Fulton et al., 1996; Imig and Navar, 1996). The main catabolic pathway for EETs is the conversion to diHETEs by soluble epoxide hyrdolase (sEH) enzyme. They can also be metabolized by ω-oxidation, β-oxidation and chain elongation; the latter two being more prominent when sEH activity is low or inhibited in the tissue (Carroll et al., 2006; Fleming, 2010). EETs are known to activate the BK channels in the smooth muscle resulting in cell membrane hyperpolarization and causing vasodilation. There is accumulating evidence that EETs activation of the BK channels in the smooth muscle requires Gαs and cAMP/ PKA (Li and Campbell, 1997; Li et al., 2002; Krotz et al., 2004; Fleming, 2010). However, studies in smooth muscle cells from rat cerebral arteries and mice mesenteric arteries suggest that EETs increase endothelial Ca^{2+} levels through activation of vanilloid type 4 transient receptor potential
(TRPV4) channels. There are also reports that $K_{\text{ATP}}$ channel contributes to EET mediated vasorelaxation (Imig, 2012; Ponnoth et al., 2012a).

**20-HETE in the regulation of vascular tone**

ω-hydroxylases consists of Cyp4a and Cyp4f families metabolize AA to 20-HETE in the liver, kidney, heart, lung, brain and vasculature. There are several different isoforms encoded by cDNA in various species. In humans these are the Cyp4a11, Cyp4f2 and Cyp4f3; in rats there are 4 of Cyp4a: Cyp4a1, Cyp4a2, Cyp4a3, Cyp4a8 and 4 Cyp4f isoforms: Cyp4f1, Cyp4f4, Cyp4f5 and Cyp4f6, and in mice Cyp4a10, Cyp4a12, and Cyp4a14 are expressed. Fibrates are known to induce Cyp4a1 and Cyp4a3 in the liver and kidney, but not in the blood vessels as they do not express peroxisome proliferator activated receptor (PPAR)-α (Sundseth et al., 1992; Zhou et al., 2006). The main pathway for their breakdown is by β-oxidation to less active shorter chain length products. The other pathways are metabolism by COX enzymes to form vasoconstrictor endoperoxides and vasodilator prostanoids (Schwartzman et al., 1989; Carroll et al., 1992; Roman, 2002).

20-HETE is a potent vasoconstrictor of renal, cerebral, mesenteric and cardiac vascular beds (EC$_{50}<$10$^{-8}$M) (Ma et al., 1993; Imig et al., 1996; Zou et al., 1996). Angiotensin II (AngII), endothelin and serotonin (5-HT) stimulate the formation of 20-HETE. Vasoconstrictor responses to these agonists are attenuated on inhibiting the 20-HETE formation (Carroll et al., 1996; Oyekan et al., 1997; Alonso-Galicia et al., 1998; Alonso-Galicia et al., 1999; Croft et al., 2000). The production of 20-HETE is inhibited by NO, carbon monoxide and superoxide radicals (Roman, 2002). PKC, mitogen activated protein kinase (MAPK), src-type tyrosine kinase and rho kinase pathways are activated by 20-HETE and all play role in the regulation of vascular tone. Furthermore,
20-HETE increases the conductance of L-type Ca\(^{2+}\) channel and inhibits BK channels through PKC activation. This allows for sustained depolarization of vascular smooth muscle and Ca\(^{2+}\) entry through L-type Ca\(^{2+}\) channel and causes contraction of the smooth muscle (Zou et al., 1996; Lange et al., 1997; Sun et al., 1998; Sun et al., 1999; Gebremedhin et al., 2000). Recent studies have implicated that 20-HETE augments the activation of inward non-selective cation currents through transient receptor potential canonical 6 channels involved in myogenic response (Basora et al., 2003; Brayden et al., 2008).

**Adenosine and Cyp450 metabolites in the regulation of vascular tone**

The interplay between adenosine and Cyp450 metabolites has come into light in past few years. Studies have shown a relationship between A\(_{2\alpha}\)AR and EETs. In rat preglomerular vessels, A\(_{2\alpha}\)AR have shown to mediate vasodilation through EETs via cAMP-PKA pathway activating BK channels (Carroll et al., 2006). Inhibition of the EETs pathway with 14,15-EEZE (EETs antagonist) decreased the NECA-induced relaxation and showed contraction at higher doses in the A\(_{2\alpha}\)WT mice aortae as compared to the untreated control (Nayeem et al., 2008). In addition, A\(_1\)AR and Cyp4a protein has been shown to be up-regulated in A\(_{2\alpha}\)KO mice, suggesting a relationship between them (Ponnoth et al., 2012a). These findings have been discussed in the subsequent chapters.

**Potassium (K\(^{+}\)) channels in the regulation of vascular tone**

There are several ion channels on the vascular smooth muscle cell surface. There are more than 4 types of K\(^{+}\) channels (Nelson et al., 1990; Nelson and Quayle, 1995; Jackson, 2000), 4 types of voltage gated Ca\(^{2+}\) channels, more than 2 types of Cl\(^{-}\) channels, store-operated Ca\(^{2+}\) channels and stretch activated cation channels (Nelson et al., 1990; Jackson, 2000).
The most dominant ion channels are $K^+$ channels and their activity plays a pivotal role in determining and regulating the membrane potential, thereby the vascular tone. There are 4 different types of $K^+$ channels: voltage gated $K^+$ ($K_V$) channels, inward rectifier $K^+$ ($K_{IR}$) channels, $K_{ATP}$ channels, and BK channels. This dissertation thesis focuses on role of BK channels in the regulation of vascular tone.

a) $K_V$ channels: They are also known as delayed rectifier channels and are expressed on the smooth muscle. They are activated by membrane depolarization with threshold potentials of approximately 30mV for substantial activation. Vasoconstrictors have a tendency to close $K_V$ channels through PKC and intracellular $Ca^{2+}$ and vasodilators open $K_V$ via cAMP signaling cascade (Nelson and Quayle, 1995).

b) $K_{IR}$ channels: These are found in both excitable and non-excitable cells. The inward $K^+$ current pass through these channels much more readily than the outward current with physiological ion gradients and with increase in extracellular $K^+$ concentration increases the channel conductance. They are known to mediate vasodilation in cerebral, coronary, skeletal muscle vascular beds through elevated extracellular $K^+$ resulting in hyperpolarization of vascular smooth muscle membrane and thereby dilation (Quayle et al., 1993).

c) BK channels: These are found in vascular smooth muscle cells. As they allow the $K^+$ channels to pass readily through them, they are also known as maxi-$K$ channels or big K channels. They have a conductance of 250pS and are activated by elevations in intracellular $Ca^{2+}$ and membrane depolarization (Nelson, 1993).

d) $K_{ATP}$ channels: These channels derive their name due to their sensitivity to intracellular ATP concentrations. They close as the ATP concentration increases.
Apart from smooth muscle; they are found in cardiac muscle, skeletal muscle, pancreatic β- cells and certain types of neurons (Nelson et al., 1990; Nelson, 1993).

**BK channels in the regulation of vascular tone**

They are known as Slo 1 as they had been cloned from the drosophila slowpoke locus (Atkinson NS, Robertson GA and Gantetzky B; Science Wash. DC 253:551-555, 1991). BK channels are composed of 4 α subunits and 1-4 β-subunits (β1-β4). The pore forming α subunit is composed of 11 hydophobic domains (S0-S10), of which membrane spanning S0-S6 domains constitute the core region with an NH₂ terminus and the remaining four domains (S7-S10) are located in cytoplasm and form the COOH terminus of the protein. The voltage sensor property of the channel is located on the S4 domain and the pore forming region on the S5-S6 linker (Toro L, Taanaka Y News Physiol Sci 13:112-117, 1998). The α subunit also contains the Ca²⁺ bowl in the tail region of the protein conferring the intrinsic sensitivity to Ca²⁺ to the protein. However, the regulator of conductance for K⁺ (RCK) domain present between the core and the tail region of the protein is also associated to Ca²⁺ sensitivity by some (Xia et al., 2002; Krishnamoorthy et al., 2005). The α subunit is encoded by Slo gene only, but has several subunits which confer different properties to the channels in various tissues like voltage sensitivity, phosphorylation by cAMP dependent PKA or PKG. The four-β subunits further add on to the variability as there are 4 subunit genes and 8 subunit proteins have been discovered with different pharmacological, modulatory effects and the activation gating of the channel. The β subunit is composed of two transmembrane domains with an extracellular domain and cytoplasmic NH₂ and COOH terminals. It enhances the voltage and the calcium sensitivity of the channel by interacting with the S0 subunit and
NH2 terminus of the α-subunit. In vascular smooth muscle cells (VSMC) β1 is the prominent one.
Figure 1.3: Structure of BK channel (Ledoux et al., 2006)

Figure 1.4: The native BK channel composed of 4-α and 4-β subunits (Ledoux et al., 2006)
Intracellular Ca^{2+} can cause dilation or constriction of the smooth muscle. A global increase in the cytoplasm Ca^{2+} concentration results in activation of the myosin light chain kinase (MLCK) and causes contraction of the smooth muscle. This global increase in calcium occurs through open state probability of the L-type voltage dependent calcium channel (L-VDCC) and regulated by the membrane potential and results in vasoconstriction. The Ca^{2+} increase from the ryanodine receptors (RyR)/ IP_3 receptors, known as Ca^{2+} sparks, generates a highly localized elevation in the Ca^{2+} levels but the global Ca^{2+} level is raised minimally. The IP_3/ RyR receptors are located in close proximity to the BK channels and the Ca^{2+} sparks activates the BK channel (Perez et al., 1999). Opening of the BK channels hyperpolarizes the membrane and promotes the closure of the L-VDCC and thus causing dilation. Thus, the Ca^{2+} sparks opposes the vasoconstriction.

BK channels play an important role in myogenic tone and contribute to the peripheral resistance. Several studies in rat cerebral, coronary and saphenous arteries have shown that increase in intracellular Ca^{2+} caused by pressure induced membrane depolarization and results in activation of BK (Brayden et al., 1991; Berczi et al., 1992).

**Adenosine and BK channels**

Adenosine relaxes vascular smooth muscle through several mechanisms, including the activation of K^+ channels (Dart and Standen, 1993). Reports regarding the role of BK channels in adenosine-induced smooth muscle relaxation vary widely. In canine coronary arterioles, vasodilation in response to adenosine is inhibited by iberiotoxin (Cabell et al., 1994). Blocking BK channels inhibits vasodilation to 2-chloro-adenosine in pig coronary arterioles (Borbouse et al., 2009); however, the role of BK channels in this response is abolished in pigs with metabolic syndrome (Borbouse et al.,
2009). Thus, it could be pathology that explains why BK channels play no role in adenosine-induced vasodilation in human coronary arterioles (Sato et al., 2005), as they are typically collected from patients with heart disease. Conversely, it may be that BK channels play little, if any role, in adenosine-induced vasodilation, as this has been reported in the majority of studies from pig coronary arterioles (Hein and Kuo, 1999; Hein et al., 2001; Heaps and Bowles, 2002). However, it cannot be ignored that BK channels are reported to contribute to adenosine-induced relaxation/vasodilation of rat cerebral arterioles (Paterno et al., 1996), rabbit renal arteries (Rump et al., 1999); rat aortas (Ray and Marshall, 2006); and rat pre-glomerular microvessels (Carroll et al., 2006). Further, adenosine increases a Ca\(^{2+}\)-dependent K\(^+\) current in smooth muscle cells from the rat mesenteric artery that may be mediated by BK channels (Li and Cheung, 2000). At present, there is little consensus regarding the role of BK channels in adenosine-induced smooth muscle relaxation and very little data directly addressing whether adenosine increases BK current in smooth muscle cells isolated from those same arteries or arterioles.
Specific Aims

Adenosine plays an important role in the regulation of vascular tone in both physiological and patho-physiological conditions, where AR expression is altered. Apart from adenosine, the Cyp450 metabolites have also been shown to have pivotal role in the regulating the tone of the blood vessels. Although the work cited above provides evidence that A\textsubscript{2A} AR and Cyp-epoxygenases-derived metabolites (EETs) do interact, but the precise mechanism by which A\textsubscript{1}AR interacts with Cyp\textsubscript{4a} and regulate the vascular tone is completely unknown.

Given the traits of A\textsubscript{1}AR and Cyp\textsubscript{4a} derived metabolite of AA (20-HETE), a relationship between the two is highly plausible. Both A\textsubscript{1}AR and 20-HETE are altered in several pathophysiological conditions. Thus, understanding the relationship between the two will help to better develop therapeutic targets. Thus, the purpose of this dissertation is to identify the relationship between A\textsubscript{1}AR and Cyp\textsubscript{4a} and elucidate the signaling pathways in the regulation of vascular tone.

With this in mind, the following aims were developed:

**Specific Aim 1:** To determine elucidate the relationship between A\textsubscript{1}AR and Cyp\textsubscript{450} and in the A\textsubscript{1}AR mediated contraction of smooth muscle

**Working Hypothesis:** Adenosine A\textsubscript{1} receptor induced -vascular contraction is mediated through Cyp\textsubscript{450} metabolite, 20-HETE

**Specific Aim 2:** To delineate the signaling pathways through which A\textsubscript{1}AR mediates vasoconstriction via 20-HETE

**Sub specific aim 2.1:** To identify the signaling mechanisms of A\textsubscript{1}AR mediated smooth muscle contraction.
**Working hypothesis:** A₁AR-20HETE mediates vasoconstriction through activation of PKC-α and p-ERK1/2 pathway.

**Sub-specific aim 2.2:** To identify the ion channels involved in A₁AR mediated contraction through 20-HETE

**Working hypothesis:** In the presence of A₁AR, 20-HETE modulates vascular response through BK channels in the aortic smooth muscle.
References


hydroxyeicosatetraenoic acid- and angiotensin II-dependent. *Hypertension* **56:**871-878.


CHAPTER TWO: ADENOSINE A1 RECEPTORS LINK TO SMOOTH MUSCLE CONTRACTION VIA CYP4a, PKC-α AND ERK1/2

Abstract

Adenosine induces contraction of smooth muscle through A₁ adenosine receptor (A₁AR), possibly via generation of arachidonic acid-derived metabolite (20-HETE) by Cyp4a. 20-HETE is important in regulation of vascular tone. We tested the hypothesis that A₁AR contraction of smooth muscle depends on Cyp4a through PKC-α-ERK 1/2 pathway. Experiments included isometric tension recordings of aortic contraction and Western blots of signaling molecules in wild type (WT) and A₁AR knockout (A₁KO) mice. Vascular responses for adenosine agonists and 20-HETE were obtained in both WT and A₁KO mice aortae and mesenteric arteries. 20-HETE formation was evaluated in-vitro from WT and A₁KO mice aortae. In addition, vascular responses to adenosine agonists with Cyp4a inhibitor and to 20-HETE with PKC-α and ERK1/2 inhibitors were studied in mice aortae. Immunoblots revealed higher Cyp4a levels in WT than A₁KO. HET0016 (Cyp4a inhibitor, 10⁻⁵M) dramatically reduced 5’-N-ethylcarboxamide adenosine (NECA, adenosine analog)-induced contraction in WT (-4.02 ± 1.2% to 3.9 ± 0.7% at 10⁻⁶M, p<0.05), and enhanced relaxation in A₁KO (16.1 ± 3.5% to 28.9 ± 6.6% at 10⁻⁶M, p<0.05). Also, 2-chloro-N⁶-cyclopentyladenosine (CCPA, an A₁AR agonist)-elicited contraction was significantly blunted with HET0016 in WT (-36.1± 1.9% to -9.4 ± 2.9% at 10⁻⁶M, p<0.05) with no effect in A₁KO. 20-HETE (10⁻⁷M) induced contraction was higher in WT than A₁KO in aortae (33.4 ± 2.9% vs. 23.9 ± 2.4%) as well as mesenteric arteries (10.5 ± 1.52% vs. 0.3 ± 1.6%). This contraction was abated in WT and A₁KO by
Gö6976 (PKC-α inhibitor) and PD98059 (ERK1/2 inhibitor). PKC-α, p-ERK1/2 and total ERK1/2 protein levels were higher in WT than A₁KO (p<0.05), and Cyp2c29 was upregulated in A₁KO. Our data indicate that A₁AR mediates smooth muscle contraction via CYP4a and a PKC-α-ERK1/2 pathway. These data suggest a relationship between A₁AR and Cyp4a, and may have important implications in cardiovascular disorders.
Introduction

Adenosine is an extracellular signaling molecule that affects heart rate, coronary blood flow, and blood pressure (Drury and Szent-Gyorgyi, 1929). Adenosine alters vascular tone by binding to one of the four G-protein coupled receptors: A₁, A₂A, A₂B and A₃. Activation of A₁ and A₃ receptors contracts vascular smooth muscle, in part, by inhibiting adenylyl cyclase through pertussis toxin-sensitive Gᵢ protein (Abbracchio et al., 1995; Tawfik et al., 2005; Jacobson and Gao, 2006). In contrast, activation of A₂A and A₂B receptors relaxes smooth muscle, in part, by stimulating adenylyl cyclase (Abbracchio et al., 1995). In the case of A₂A receptors, this process occurs through Gₛ and Gₒᵢᵣ proteins, whereas A₂B receptors utilize Gₛ and Gₕ proteins (Abbracchio et al., 1995). In addition to G protein signaling, activation of adenosine receptors also leads to the metabolism of arachidonic acid and the production of myriad signaling molecules (Cheng et al., 2004).

Metabolites of arachidonic acid regulate smooth muscle tone, including prostaglandins, thromboxanes, leukotrienes, and hydroxyeicosatetraenoic acids (HETEs) (Hoagland et al., 2001; Roman, 2002; Miyata and Roman, 2005). Two subfamilies of cytochrome P450 (CYP) enzymes metabolize arachidonic acid: CYP-epoxygenases and ω-hydroxylases (Miyata and Roman, 2005). The CYP-epoxygenases produce epoxycosatrienoic acids (EETs), which relax smooth muscle. In contrast, the ω-hydroxylases such as CYP4a and CYP4f produce 20-HETE, which contracts smooth muscle (Harder et al., 1994; Zou et al., 1996; Lange et al., 1997; Nayeem et al., 2008; Ponnoth et al., 2012a). The mechanisms linking CYP4a to smooth muscle contraction, however, are not entirely clear, especially in regard to adenosine A₁ receptor activation.
20-HETE-induced contraction of smooth muscle appears to involve protein kinase C (PKC), Src-type tyrosine kinase, rho kinase and mitogen activated protein kinase (MAPK) pathways (Lange et al., 1997; Sun et al., 1999; Obara et al., 2002; Williams et al., 2010). We have demonstrated previously that A₁ receptor stimulation is linked to PKC-α and ERK1/2 activation in coronary artery smooth muscle (Ansari et al., 2009). Gaps in our knowledge remain to be addressed, the most important of which pertain to whether A₁-dependent activation of PKC-α and ERK1/2 results in smooth muscle contraction. Thus, the aim of the present study was to delineate mechanisms downstream of A₁ receptor activation that lead to smooth muscle contraction. We tested the hypothesis that adenosine A₁ receptors contract smooth muscle through a pathway involving CYP4a, PKC-α, and ERK1/2.
Methods

Animals: Some of the A<sub>1</sub>KO mice were obtained from Dr. Jurgen Schnerrmann (NIDDK, NIH) on C57BL/6 background. C57BL/6 (WT) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Equal number of males and females of 14-18 weeks of age were used in our studies, as no gender differences were observed in the responses to the pharmacological agents used. The Institutional Animal Care and Use Committee of West Virginia University approved this study.

Isometric tension: Following anesthesia with pentobarbital sodium (100 mg/kg, i.p.), the aorta was removed and cut into 3-4 mm rings. Rings were mounted on stainless steel wires and suspended in 10 ml organ baths filled with Krebs-Henseleit buffer containing (in mM): 118 NaCl, 4.8 KCl, 1.2 MgSO<sub>4</sub>, 1.2 KH<sub>2</sub>PO<sub>4</sub>, 25 NaHCO<sub>3</sub>, 11 glucose and 2.5 CaCl<sub>2</sub>. Baths were maintained at 37°C and bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub> (pH 7.4). Rings were equilibrated for 90 min under a resting tension of 1 g. Rings were contracted with 50 mM KCl twice to check viability. Rings were then treated with submaximal phenylephrine (PE; 1 µM) to obtain a stable contraction and integrity of the vascular endothelium was confirmed by relaxation to acetylcholine (1 µM). Tension was monitored continuously with a digital acquisition system and analyzed using Acknowledge 3.5.7 software (BIOPAC). Our laboratory previously validated all methods (Tawfik et al., 2005; Ansari et al., 2007a; Ponnoth et al., 2008; Ansari et al., 2009).

Concentration-response curves for 5'-N-ethylcarboxamido adenosine (NECA; 10<sup>-11</sup>-10<sup>-5</sup>M), 2-chloro-N (6) cyclo-pentyl-adenosine (CCPA; 10 pM to 10 µM) were run in parallel in aortic rings from WT and A<sub>1</sub>KO mice. In all experiments, drugs were administered to yield the next higher concentration only when the previous response reached steady state. 20-HETE (Cayman Chemical; Ann Arbor, MI) concentration-
response curves were constructed, but in some experiments a single concentration (100 nM) was used as described previously (Alonso-Galicia et al., 1998; Obara et al., 2002; Wu and Schwartzman, 2011; Singh et al., 2012). Inhibitors of CYP4a (HET0016; Cayman Chemical), PKC-α, (Gö6976; Calbiochem; La Jolla, CA), and ERK1/2 (PD98059; Calbiochem) were added 30 min prior to contraction with PE (10^{-6}M) and present throughout the experiments. Inhibitor concentrations were determined by others and us (Loufrani et al., 1999; Ansari et al., 2001; Cogolludo et al., 2003; Ding et al., 2004; Sakwe et al., 2005; Nayeem et al., 2008; Ansari et al., 2009; Chang et al., 2009; Matsumoto et al., 2011; Ponnoth et al., 2012a). Acetylcholine and PE were dissolved in distilled water, while NECA, CCPA, HET0016, Gö6976, and PD98059 were dissolved in DMSO. We have shown that previously these vehicles have no effect on smooth muscle contraction (Ansari et al., 2007a). 20-HETE was dissolved in ethanol and had no effect on the vasoconstrictive properties of the drug. Percentage of contraction was determined as a percent change from the maximum phenylephrine (PE) response. If A = maximum total tension in the presence of PE; B = maximum total tension when a drug is added after PE; C = minimum passive tension determined after the experiment, after a final wash; D = PE-induced active tension = A minus C. Thus, % contraction = [(B – A) / D] X 100%

**Immunoblots:** Aortae from WT and A1KO mice were homogenized with 150 µL RIPA, (Cell Signaling Technology); 20 mM Tris-HCl (pH 7.5),(150 mM NaCl, 1 mM Na_{2}EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na_{3}VO_{4}, 1 µg/ml leupeptin), vortexed, and centrifuged for 10 min at 13,800 g at 4°C. Supernatants were stored at -80°C. Protein was measured using the Bradford dye procedure with bovine serum albumin (BSA) as a standard (Bio-Rad Laboratories; Hercules, CA). The protein extract
was divided into aliquots and stored at -80°C. Samples (25 µg of total protein) were loaded on slab gels (10% acrylamide; 1 mm thick), separated by SDS-PAGE, and transferred to nitrocellulose membranes (Hybond-ECL). Protein transfer was confirmed by visualization of prestained molecular weight markers (Bio-Rad). Membranes were blocked with 5% nonfat dry milk and incubated with primary antibody. 1:1000 dilutions were used for CYP4a (Abcam; Cambridge MA) and PKC-α (BD Transduction Labs; San Diego, CA) antibodies, while 1:500 dilutions were used for total ERK1/2 and p-ERK1/2 (both from Santa Cruz Biotechnology; Santa Cruz, CA) and 1:5000 for Cyp2c29 (Dr. Darryl C. Zeldin(NIH/NIEHS)). The phospho-ERK1/2 blots were stripped at room temperature for 15 minutes and re-probed for total-ERK1/2. All membranes were stripped and probed for β-actin (Santa Cruz); this served as an internal control to normalize protein expression in each lane. Secondary antibodies were horseradish peroxidase-conjugated. Membranes were developed using enhanced chemiluminescence (AmershamBioSciences) and X-ray film.

Measurement and analysis of 20-HETE formation rates

Equal numbers of male and female aortae were isolated on ice from WT and A1KO mice. Microsomes were prepared by pooling the aortae and homogenizing in 50mM/L Tris buffer (pH7.4) containing 150mM KCl, 0.1mM DTT, 1mM EDTA and 20% glycerol. Each sample consisted of six aortae (n=1). Microsomal fractions were isolated by differential centrifugation as previously described by us (Nayeem et al., 2008) and Dr. Poloyac’s group (Poloyac et al., 2006; Miller et al., 2009) . Microsomal fractions containing 100µg total protein and 25µM AA were incubated in 1ml of 0.12M KH2PO4 buffer containing 5mM MgCl2. Reactions were initiated by addition of 1mM NADPH at 37°C for an hour and were terminated by placing the reaction tubes on ice. 0.75ng of 20-
HETE d6 was added as an internal standard to each sample. HETE metabolites were separated along with others via reverse phase ultra-performance liquid chromatography (UPLC; Milford, MA) with an Acquity UPLC BEH C18 1.7µM, 2/1x100 mm column as previously described (Miller et al., 2009). Analysis was carried out on the TSQ operated in negative electrospray ionization-selected reaction monitoring mode with unit resolutions at both Q1 and Q3 set at 0.70 full width at half maximum. The selected reaction monitoring transitions that were monitored were as follows: 20-HETE mass-to-charge ratio \((m/z)\) 319.3 → 245.0; and 20-HETE-d6 (internal standard) \(m/z\) 325.3 → 251.0. Collision energy was optimized for each transition and ranged from 11 to 25eV with a total scan time of 0.01 s. Parameters were optimized to obtain the highest \([M-H]^+\) ion abundance and were as follows: capillary temperature 270°C, spray voltage 3,800 kV, and source collision-induced dissociation set at 1 V. Sheath gas, auxiliary gas, and ion sweep gas pressures were set to 60, 50, and 0 psi, respectively. Collision gas pressure was set to 1.2 mTorr. The data from two separate experiments have been combined for a significant ‘n’.

**Real Time PCR**

The aortic tissues from WT and A1KO were processed for total RNA isolation using the TRI reagent (MRC, Cincinnati, OH) followed by purification of the RNA in aqueous phase and removal of genomic DNA by an RNeasy Plus Micro Kit (QIAGEN, Hilden, Germany). This was followed by conversion of 0.5 g of total RNA into cDNA using High Capacity cDNA archive kit (Applied Biosaystems, Foster City, CA) in a total volume of 20 µl. Real-time PCR was performed using an ABI PRISM 7300 Detection System (Applied Biosystems) using Taqman Universal Mastermix (Applied Biosystems, Branchburg, NJ) according to the instructions of the manufacturer. The reaction volume
(20 µl) consisted of 10 µl of 2X Taqman Universal Mastermix, 4 µl of cDNA, and 1 µl of 20X FAM-labeled Taqman gene expression assay. For the real-time PCR of the concerned genes (Cyp4a10, A1AR, A2AAR, A2BAR and A3AR), the Taqman inventoried assays on-demand gene expression products were purchased from Applied Biosystems (Foster City, CA). 18S rRNA (ribosomal RNA) was used as an endogenous control. The fold difference in expression of target cDNA was determined using the comparative cycle threshold (Ct) method as described earlier (Livak and Schmittgen, 2001).

**Statistical Analysis:** Data are expressed as mean ± SEM from n number of mice. Concentration-response curves and 20-HETE/inhibitor experiments were analyzed by 2-way analysis of variance (ANOVA). Comparisons of two densitometry values were made with unpaired t-tests. P < 0.05 was considered significant in all tests.
Results

Cyp4a protein levels in WT and A₁KO mice:

Immunoblot analysis showed a ~25% decrease in Cyp4a protein levels in A₁KO as compared to WT (74.5 ± 3.7% vs. 100 ± 10.61%, Fig. 2.1A). However, there was no difference in Cyp4a10 mRNA levels (Fig 2.1B).

Effect of Cyp4a inhibitor (HET0016) on NECA and CCPA induced vascular responses in aorta:

To verify if Cyp4a plays a role in A₁AR mediated vasoconstriction, we investigated the effect of Cyp4a inhibitor, HET0016 on NECA (a non-selective adenosine agonist) and CCPA (an A₁AR agonist)-induced vascular responses. We found that NECA-elicited contraction in WT (-4.02 ± 1.2%; 10⁻⁶M; Fig. 2.1A; closed squares) was changed to significant relaxation in the A₁KO mice (16.1 ± 3.5%; 10⁻⁶M; Fig 2.1A; closed circles). Relative to the WT mice, HET0016 alleviated the NECA-induced contraction (3.97 ± 0.7%; 10⁻⁶M; Fig 2.1A; open squares). Similarly, in A₁KO mice, Cyp4a inhibition enhanced the relaxation from 16.05 ± 3.5% to 28.96 ± 6.6% (fig2.1A; open circles) compared to the litter-matched controls at 10⁻⁶M NECA (Fig 2.1A). There was a significant difference between the treated WT and A₁KO with HET0016 (3.97 ± 0.7% vs. 28.96 ± 6.6%; 10⁻⁶M NECA; Fig 2.1A). CCPA-evoked contraction in the WT (-36.1 ± 1.9%; 10⁻⁶M; Fig 2.2B; open circles) was significantly changed to relaxation in the A₁KO (11.4 ± 8.5%; 10⁻⁶M; closed circles). Pharmacological inhibition of Cyp4a (HET0016) blunted the CCPA induced contraction by 26.7% from -36.1 ± 1.9% to -9.4± 2.9% (p<0.05) at 10⁻⁶M in WT mice (Fig 2.2B; open squares). CCPA induced vascular responses were unaltered in both the treated and untreated A₁KO littermates as shown in
Fig 2.2B (closed squares). However, on treatment with the $Cyp4a$ inhibitor, the CCPA response showed higher relaxation in $A_1$KO (11.3 ± 8.5%; $10^{-6}$M) as compared to WT (-9.4 ± 2.9%; $10^{-6}$M). ACh-induced response in WT (47 ± 2%) was not significantly different from $A_1$KO (51 ± 3%, p>0.05) (Fig 2.2C). These results are consistent with those demonstrated by Wang Y et al (Wang et al., 2010) in mouse aorta.

**Effect of 20-HETE on vascular responses, and 20-HETE formation rates in $A_1$KO and WT animals:**

We further investigated the effect of 20-HETE on vascular responses in both WT and $A_1$KO mice aortae and mesenteric arteries, and determined the in vitro 20-HETE formation rate in WT and $A_1$KO aortic microsomes. As shown in Fig 2.3E, 20-HETE elicited vasoconstriction in the WT, showed similar trend of being significantly higher in both the aortae (59.18±6.09% vs. 41.32±4.49%) and the mesenteric arteries (10.2±1.52% vs. 0.3±1.6%), compared to $A_1$KO mice. We observed an unexpected increase in the contraction on addition of lowest concentration of $10^{-11}$M 20-HETE in both WT and $A_1$KO (Fig. 2.3D) mice aortae. Furthermore, 20-HETE formation rate was observed to be significantly higher in aortic microsomes from WT (0.31±0.012 pg/mol/min) than the $A_1$KO (0.23±0.018 pg/mol/min; Fig 2.4).

**$Cyp2c29$ protein levels in WT and $A_1$KO mice:**

Measurement of $Cyp2c29$ showed an up-regulation of the protein by 73% in $A_1$KO mice aortae, relative to its WT counterpart (172.7 ± 12.1% vs. 100 ± 23.04%, Fig 2.5A). Subsequently, we determined the effect of Cyp-epoxygenases inhibition on CCPA induced aortic response. In the WT littermates, MSPPOH (Cyp-epoxygenases inhibitor;
10⁻⁵M), increased the CCPA-induced contraction by 15.3% from -32.5 ± 1.7% to -47.8 ± 6% at 10⁻⁷M (Fig. 4). Likewise, in A₁KO mice, MSPPOH treatment increased the vascular response by 19.3% from 5.8 ± 4% to -13.5 ± 7.4% at 10⁻⁷M (Fig. 2.5B).

**Role of PKC-α in 20-HETE-induced contraction**

20-HETE (100 nM), a CYP4a product, contracted aortae from WT and A₁KO mice (Fig. 2.6B); however, the contractile response was less in aortic rings from A₁KO mice. Inhibition of PKC-α (100 nM Gö6976) reduced 20-HETE-induced contraction in aortic rings from both WT (by 37%) and A₁KO (by 29%) mice (Fig. 2.6B). The relative inhibitory effect of Gö6976 was the same in aortic rings from WT and A₁KO mice (Fig. 2.6C). PKC-α protein was expressed in aortae from WT and A₁KO mice (Fig. 2.6A); however, the expression of PKC-α was lower (by 47%) in A₁KO mice (p<0.05).

**Role of ERK1/2 kinase in 20-HETE-induced contraction**

The CYP4a product 20-HETE (100 nM) contracted aortic rings from both WT and A₁KO mice (Fig. 2.7B); however, the contractile response was less in aortae from A₁KO mice. Inhibition of ERK1/2 (1 µM PD98059) reduced 20-HETE-induced contraction in aortae from WT (by 48%) and A₁KO (by 36%) mice (Fig. 2.7B). The relative inhibitory effect of PD98059 was similar in aortic rings from WT and A₁KO mice (Fig. 2.7C). ERK1/2 protein was expressed in aortae from WT and A₁KO mice (Fig. 2.7A); however, the expression of total ERK (by 35%) and phospho-ERK (by 15%) were lower in A₁KO mice (p<0.05).
Figure 2.1: Cyp4a protein and mRNA levels in WT and A\textsubscript{1}KO.

Western blots for CYP4a expression in the aorta (A). Mouse isoform Cyp4a10 levels in WT and A\textsubscript{1}KO mice aortae (B). Data are expressed as mean ± SEM; n=6-8mRNA level. *p < 0.05 between WT and A\textsubscript{1}KO
Figure 2.2: Effect of Adenosine Receptor agonists’ and acetylcholine -induced responses in WT and A₁ KO aortae and mesenteric arteries

(A) Non selective adenosine agonist NECA mediated responses with Cyp4a inhibitor (10 µM HET0016); *p<0.05 between A₁KO and WT; #p<0.05 between WT +HET0016 and WT; $p<0.05 between A₁KO + HET0016 and WT + HET0016; ¥p<0.05 between A₁KO + HET0016 and A₁KO. Data are expressed as mean ± SEM (n=6-12); (B) The A₁-selective agonist CCPA-mediated contractions with CYP4a inhibitor (10 µM HET0016), *p < 0.05 between WT and A₁KO and †p < 0.05 between WT and WT + HET0016 (n=4-12). (C) Acetylcholine (ACh) responses in WT and A₁KO mice aortae and mesenteric arteries responses. *p < 0.05 between WT and A₁KO (n=6-12).
Figure 2.3: Effect of the CYP4a product, 20-HETE on smooth muscle contraction from WT and A1KO mice.

(A) Representative traces for concentration response curve for solvent (ethanol) in WT mice aortae (n=4). (B) Representative traces for concentration response curve for 20-HETE in WT mice aortae. (C) Representative traces for concentration response curve for 20-HETE in A1KO mice aortae. (D) Exogenous 20-HETE contracts aortic smooth muscle in a concentration-dependent manner. *p < 0.05 between WT and A1KO mice (n=8-12) (E) Exogenous 20-HETE responses in aortae and mesenteric arteries. Data are expressed as mean ± SEM (n=8). *p<0.05 compared to the WT in the respective tissue
Figure 2.4: 20-HETE formation rate in microsomes from WT and A1KO mice aortae (n=6-8)

Data are expressed as mean ± SEM.
Figure 2.5: Role of Cyp2c29 in WT and A$_1$KO

(A) Cyp2c29 protein levels in aortae from WT and A$_1$KO. Data are expressed as mean ±SEM and are presented as representative blot from 6 individual samples, *p<0.05 as compared to WT

(B) Effect of Cyp–epoxygenase inhibitor (MSPPOH; 10$^{-5}$M) on CCPA induced vascular response: Data are expressed as mean ± SEM (n=10). * p<0.05 compared to the WT, #p<0.05 compared to WT + MSPPOH, $p<0.05$ compared to A$_1$KO.
Figure 2.6: Effect of PKC-α on WT and A₁KO contractile responses to 20-HETE.

(A) Western blots for PKC-α protein and β-actin; (B) Aortic smooth muscle contractions in response to 100 nM 20-HETE are shown for WT and A₁KO mice with or without inhibition of PKC-α (100 nM Gõ6976); (C) The inhibitory effect of Gõ6976 on 20-HETE-induced contractions is equivalent in WT and A₁KO mice, suggesting that the relative importance of PKC-α is unchanged. Data are expressed as mean ± SEM; n = 6-16 mice; *p < 0.05 between WT and A₁KO; †p < 0.05, WT, A₁KO vs. WT + Gõ6976 & A₁KO+ Gõ6976.
Figure 2.7 Effect of ERK 1/2 on WT and A1KO mice aortae contractile responses

(A) Western blots for total ERK1/2, phosphor-ERK1/2 and β-actin expression in the aorta; (B) Aortic contractile responses to 100 nM 20-HETE are shown for WT and A1KO mice with or without inhibition of ERK1/2 (1 µM PD98059); (C) The inhibitory effect of PD98059 on 20-HETE-induced contractions. n=8-16* p < 0.05 between WT and A1KO; ‡p < 0.05, WT, A1KO vs. WT + PD98059 & A1KO+ PD98059, respectively.
This figure illustrates our understanding of signaling from the A<sub>1</sub> receptor to smooth muscle contraction. Adenosine A<sub>1</sub> receptors (A<sub>1</sub>R) are sensitive to CCPA and coupled to phospholipase C (PLCX) by G-proteins (G<sub>x</sub>). Candidates for PLCX include PLCβ1, PLCβ3, and PLCγ1, while candidates for G<sub>x</sub> include G<sub>i</sub>, G<sub>o</sub>, G<sub>q</sub>, G<sub>11</sub> as well as G-βγ subunits (Jacobson and Gao, 2006; Ansari et al., 2009). PLCX produces two second messengers from phosphatidylinositol 4,5 bisphosphate: diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP<sub>3</sub> which releases Ca<sup>2+</sup> from the sarcoplasmic reticulum; SR). DAG can be metabolized by di- and monoacylglycerol lipases to produce arachidonic acid (AA). CYP4a metabolizes AA into 20-HETE, which activates PKC-α (DAG is also an activator; PKC- β and γ isoforms are also expressed (Ansari et al., 2009). The ERK1/2 pathway is activated downstream of PKC-α. The culmination of this signaling is to contract smooth muscle through effects on, e.g., myosin light chain kinase (MLCK), myosin light chain phosphatase (MLCP), and thin filament regulatory proteins. Inhibiting CYP4a with HET0016 blocks CCPA-induced smooth muscle contraction (Fig. 2.1 and 2.2). Gö6976 and PD98095, which inhibit PKC-α and ERK1/2, inhibit smooth muscle contraction in response to 20-HETE (Fig. 2.6 and Fig 2.8)
Discussion

It is well documented that A₁AR on activation mediates vasoconstriction through G<sub>i</sub> and G<sub>o</sub> proteins (Jacobson and Gao, 2006). Our data show that NECA-evoked contraction in WT was lower in the A₁KO mice aortae (Fig. 2a). We also observed in the aortic tissue that CCPA-induced contraction was completely abolished in A₁KO (Fig. 2b). Our results are consistent with previous findings from our laboratory and others (Tawfik et al., 2005; Wang et al., 2010). We have found that NECA and CCPA induced responses in the mesenteric arteries are similar to those found in the aortae as reported earlier from our laboratory (Teng et al., 2011). The contractile responses elicited by these adenosine agonists are similar to those found in a wide variety of systems like mouse afferent arterioles (Hansen et al., 2003), human cultured prostatic stromal cells (Preston et al., 2004), cat esophageal smooth muscle cells (Shim et al., 2002), guinea pig aorta (Ford and Broadley, 1999) and mouse coronary artery cells, heart, aorta and carotid artery (Prentice et al., 2002; Talukder et al., 2002; Ansari et al., 2009).

The first evidence of an interaction between A₁AR and Cyp4a is the significantly lower levels of Cyp4a protein expression in the A₁KO mice as compared to the WT (Fig.1). To further examine, the functional interplay between Cyp4a and A₁AR, we studied the effect of Cyp4a inhibition on adenosine agonists’ elicited contractile responses in WT and A₁KO mice aortae. Due to the similar responses to adenosine agonists in the mice mesenteric arteries and aortae, we used aortae for these studies. HET0016 dramatically reduced the contraction responses induced by NECA, in both the WT and the A₁KO mice aortae (Fig. 2a). Moreover, there was a
significantly higher relaxation observed in NECA-induced aortic responses in A1KO with the pharmacological inhibition of Cyp4a (Fig. 2a). This suggested that Cyp4a may play a part in the A1AR mediated vasoconstriction. The above findings were confirmed when Cyp4a inhibitor, HET0016 attenuated the vasoconstriction evoked by the A1 agonist, CCPA in the WT with no significant difference in the treated (HET0016) and untreated A1KO tissues (Fig. 2b). However, we observed a significant difference in both the NECA and CCPA induced vascular responses in the HET0016 treated WT and A1KO tissues (Fig 2). These results clearly implicate a role for Cyp4a in A1AR mediated vasoconstriction. These findings are congruent with previous studies in our lab (Nayeem et al., 2009) and others as well, which have shown an inhibition of Cyp4a with HET0016 in renal interlobar arteries from Sprague Dawley rats (Sodhi et al., 2010) and human and rat cerebral arteries (Toth et al., 2011).

20-HETE is a potent vasoconstrictor of renal, mesenteric, skeletal and cerebral arterioles across several species (Roman, 2002). Several investigators have shown that in both circulatory and pulmonary vascular beds, 20-HETE mediates vasoconstriction by uncoupling of nitric oxide synthase, resulting in reduction of endothelial dependent relaxation (Frisbee et al., 2000; Singh et al., 2007; Cheng et al., 2008). Our data show that 20-HETE vascular responses in aortae and mesenteric arteries are lower in A1KO as compared to the WT (Fig.3a). Moreover, the Cyp4a functional activity evaluated by the 20-HETE formation rates in the aortic microsomes were found to be lower in the A1KO (Fig 3b) as compared to the WT mice. This further underscores the role of Cyp4a in A1AR mediated vasoconstriction.
There is a dynamic interplay between the metabolites of the two pathways of \textit{Cyp450} enzymes, EETs and 20-HETEs, in the modulation of vascular homeostasis. EETs are considered to be endothelium-derived hyperpolarizing factors that induce hyperpolarization of the endothelial cells and vascular smooth muscle cells resulting in vasodilation. 20-HETE in vascular smooth muscle causes vasoconstriction by depolarization of vascular smooth muscle cell (Miyata and Roman, 2005)(Miyata and Roman, 2005)(Miyata and Roman, 2005). As \textit{Cyp4a} and \textit{Cyp2c} products have functionally antagonistic effects, we investigated if \textit{Cyp2c29} has any relationship to the A
\textsubscript{1}AR mediated vascular responses. We observed that \textit{Cyp2c29} protein levels were significantly up- regulated in A
\textsubscript{1}KO mice as compared to the WT (Fig S.3.5). Since we have seen an up-regulation of \textit{Cyp2c29} in A
\textsubscript{1}KO compared to WT mice, it is quite possible that relaxation observed in A
\textsubscript{1}KO mice by \textit{Cyp4a} inhibition is due to \textit{Cyp2c29} product EETs and due to the inhibition of \textit{Cyp4a} that limits the production of 20-HETE. This observation was confirmed by the enhanced CCPA mediated vasoconstriction in the presence of the Cyp-epoxygenase inhibitor, MSPPOH (Fig.S.3.6). We have shown earlier that \textit{Cyp4a} protein levels are up regulated with MSPPOH treatment (Nayeem et al., 2008). In the WT, although \textit{Cyp}-epoxygenases were inhibited, a higher contraction observed with MSPPOH treatment is due to higher levels of \textit{Cyp4a} and in the A
\textsubscript{1}KO, the higher vascular response is due to inhibition of the \textit{Cyp}-epoxygenases. Thus, the down-regulation of \textit{Cyp4a} and an up-regulation of \textit{Cyp2c29} protein levels promote the relaxation observed in the A
\textsubscript{1}KO littermates. This inverse relationship between \textit{Cyp4a} and \textit{Cyp2c} is consistent with findings from other investigators in rat afferent arterioles and preglomerular arterioles (Hercule and Oyekan, 2000; Imig et al., 2000).
Several studies have reported that 20-HETE promotes constrictor responses by activating PKC, Src type tyrosine kinase, rho kinase and the MAPK pathways (Lange et al., 1997; Sun et al., 1999; Obara et al., 2002; Williams et al., 2010). Moreover, adenosine subsequent to binding to its receptors induces signaling cascades by activating MAPK through G-protein coupled mechanism. In addition, our laboratory has shown that in mouse coronary artery smooth muscle cells, A₁AR mediates vasoconstriction through PKC-α, leading to phosphorylation of p42/44 mitogen activated protein kinase (MAPK) via PLC β-III (Ansari et al., 2009). Given this evidence, we investigated the effect of PKC-α and ERK1/2 inhibition on 20-HETE induced contraction in both WT and A₁KO mice. The basal protein levels of PKC-α, p-ERK1/2 and total ERK1/2 are higher in the WT as compared to the knockout littermates (Figs. 5 and 7). The lower PKC-α and p-ERK1/2 protein levels in the A₁KO mice are consistent with our previous findings in the A₁KO mouse coronary artery smooth muscle cells (Ansari et al., 2009). Exogenous administration of 20-HETE produced similar higher contraction response in WT than the A₁KO, both in the mice aortae and mesenteric arteries (Fig 3), thus, suggesting that the signaling proteins downstream of 20-HETE are essential in Cyp4a modulation of A₁AR mediated vasoconstriction. The use of a specific PKC-α blocker, Gö6976, attenuated the 20-HETE mediated vasoconstrictor response in WT and A₁KO mice aortae (Fig. 6). Similarly, pharmacological inhibition of ERK1/2 with PD98059 decreased the 20-HETE-elicited contraction in the WT and almost abolished the contractile tone in the A₁KO (Fig. 8). However, the greater blockade of the vasoconstrictor responses with ERK inhibitor than with the PKC-α inhibitor implies
that MAPK pathway activation may involve several kinases like PKA, PKC, rho kinases or Ras activation or a cross talk between the different tyrosine kinase receptors. These data substantiate the role of PKC-α and ERK1/2 in A₁AR mediated vasoconstriction through 20-HETE.

Our current understanding of signaling for A₁ → CYP4a → PKC-α → ERK pathway is summarized in Fig. 4. A₁ receptor activation with, e.g., CCPA, activates CYP4a which metabolizes AA into 20-HETE. CCPA-induced contractions are almost entirely dependent upon signaling through CYP4a, as inhibition with HET0016 abrogates contraction (Fig. 3.1A). 20-HETE activates PKC-α and this is integral to contraction, as Gö6976 blocks the response (Fig. 3.3). The ERK1/2 pathway is activated downstream of PKC-α, as Gö6976 blocks ERK activation (Ansari et al., 2009) and PD98059 blocks the contraction (Fig. 3.3). ERK1/2 integrates the signaling for contraction and transduces it to, e.g., myosin light chain kinase (MLCK), myosin light chain phosphatase (MLCP), and thin filament regulatory proteins.

In summary, we have shown that A₁ receptor activation leads to smooth muscle contraction via CYP4a, PKC-α, and ERK 1/2. Because A₁ receptors and 20-HETE are implicated in a variety of cardiovascular disorders, a better understanding of this pathway will be important for identifying therapeutic targets and treatment opportunities.
References


Drury AN and Szent-Gyorgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68: 213-237, 1929.

Ford WR and Broadley KJ. Effects of adenosine receptor agonists on induction of contractions to phenylephrine of guinea-pig aorta mediated via intra- or extracellular calcium. Gen Pharmacol 33: 143-150, 1999.


Sakwe AM, Rask L, and Gylfe E. Protein kinase C modulates agonist-sensitive release of Ca2+ from internal stores in HEK293 cells overexpressing the calcium sensing receptor. *J Biol Chem* 280: 4436-4441, 2005.


CHAPTER THREE: ADENOSINE A$_1$ RECEPTORS INHIBIT BK CHANNELS THROUGH PKC-$\alpha$ DEPENDENT MECHANISM IN MOUSE AORTIC SMOOTH MUSCLE CONTRACTION

Abstract

Adenosine receptors (AR; A$_1$, A$_{2A}$, A$_{2B}$, and A$_3$) contract and relax smooth muscle through different signaling mechanisms. Deciphering these complex responses remains difficult because relationships between AR subtypes and various end-effectors (e.g., enzymes and ion channels) remain to be identified. A$_1$AR stimulation is associated with the production of 20-hydroxyeicosatetraenoic acid (20-HETE) and activation of protein kinase C (PKC). 20-HETE and PKC can inhibit large conductance Ca$^{2+}$/voltage-sensitive K$^+$ (BK) channels that regulate smooth muscle contraction. We tested the hypothesis that activation of A$_1$AR inhibits BK channels via a PKC-dependent mechanism. Patch clamp recordings and Western blots were performed using aortae of wild type (WT) and A$_1$AR knockout (A$_1$KO) mice. There were no differences in whole-cell K$^+$ current or $\alpha$ and $\beta$1 subunits expression between WT and A$_1$KO. 20-HETE (100 nM) inhibited BK current similarly in WT and A$_1$KO mice. NECA (5'-N-ethylcarboxamidoadenosine; 10 $\mu$M), a non-selective AR agonist, increased BK current in myocytes from both WT and A$_1$KO mice, but the increase was greater in A$_1$KO (52±15 vs. 17±3%; p<0.05). This suggests that A$_1$AR signaling negatively regulates BK channel activity. Accordingly, CCPA (2-chloro-N(6)-cyclopentyladenosine; 100 nM), an A$_1$AR-selective agonist, inhibited BK current in myocytes from WT but not A$_1$KO mice (81±4 vs. 100±7% of control; p<0.05). Gö6976 (100 nM), a PKC$\alpha$ inhibitor, abolished the effect of CCPA to inhibit BK current (99±3% of control). These data lead us to conclude that, in aortic smooth muscle, A$_1$AR inhibits BK channel activity and that this occurs via a mechanism involving PKC$\alpha$. 
Introduction

Adenosine exerts its effects through four G-protein coupled receptors: the known adenosine receptor (AR) subtypes are A₁, A₂A, A₂B and A₃. These AR subtypes play important roles in vascular reactivity, as A₁AR and A₃AR contract smooth muscle, whereas A₂AAR and A₂BAR relax smooth muscle (Fredholm et al., 2001; Tawfik et al., 2005; Jacobson and Gao, 2006; Ansari et al., 2007b; Ponnoth et al., 2009). It is well accepted that metabolites of arachidonic acid (AA) regulate vascular tone; however, only recently have these pathways been recognized to function downstream of A₁AR and A₂AAR (Harder et al., 1997; Cheng et al., 2004; Nayeem et al., 2008; Ponnoth et al., 2012a). Epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) are produced from arachidonate by epoxygenases and ω-hydroxylases, respectively. EETs are considered to be endothelium-derived hyperpolarizing factors that activate Ca²⁺-dependent K⁺ channels and Na⁺-K⁺-ATPase (Roman et al., 2000). 20-HETE in vascular smooth muscle functions as a second messenger to promote depolarization, Ca²⁺ influx, and contraction of vascular smooth muscle that acts, in part, through protein kinase C (PKC) (Miyata and Roman, 2005; Williams et al., 2010).

Ion channels are important determinants of vascular tone, as they control membrane potential and the intracellular Ca²⁺ concentration. Large conductance, Ca²⁺/voltage-sensitive K⁺ (BK) channels participate in this electromechanical coupling (Nelson et al., 1995; Brenner et al., 2000). BK channels are activated by membrane depolarization and increases in intracellular Ca²⁺. 20-HETE has been shown to inhibit BK channels in canine basilar artery (Obara et al., 2002) and rat renal arterioles (Zou et al., 1996). BK channels can also be regulated by phosphorylation and are targets of PKC, which reduces open probability (Zhou et al., 2009).
We have shown previously that activation of A1AR couples with the Cyp4a metabolite, 20-HETE and mediates contraction of the aortic smooth muscle through a pathway involving PKCα and/or p-ERK1/2. However, genetic ablation of the A1AR reduced the contractions in response to 20-HETE, in part, by reducing the expression of downstream signaling molecules (PKCα and p-ERK1/2) (Kunduri et al., 2013). To further understand the signaling transduction of A1AR and 20-HETE, we performed studies designed to test the hypothesis that activation of A1AR inhibits BK channels via a PKC-dependent mechanism.
Materials and Methods

Animals

A1KO mice (originally obtained from Dr. Jurgen Schnermann, NIDDK, NIH) were on C57BL/6 background. A1KO mice were backcrossed 4 generations with C57BL/6 (WT); genotypes were confirmed by polymerase chain reaction. C57BL/6 (WT) mice (originally purchased from The Jackson Laboratory, Bar Harbor, ME) were bred in-house. Equal number of males and females of 14-18 weeks of age were used in our studies, as no gender differences were observed. The Institutional Animal Care and Use Committee of West Virginia University provided regulatory oversight and protocols followed guidelines set forth in The Guide for the Care and Use of Laboratory Animals (National Research Council, 2011). Mice had free access to food and water and were housed on a 12:12 hr light-dark cycle. Mice were killed with an overdose of sodium pentobarbital (150 mg/kg ip) and aortae were quickly harvested into ice-cold physiological saline solution. Adipose and connective tissue were removed under the magnification of a dissecting microscope.

**Isometric tension:** Isometric tension experiments were conducted with small segments of WT and A1KO mice aortae as described previously in (Kunduri SS et al, 2012). After equilibration, the responsiveness and stability of individual rings were checked by administration of PE (10^{-6} M) (Ansari et al., 2007b; Ponnoth et al., 2008; Ansari et al., 2009). The integrity of the vascular endothelium was assessed pharmacologically by acetylcholine (ACh, 10^{-6} M) (Ansari et al., 2007a; Ansari et al., 2009) to produce relaxation of PE pre-contracted rings. The rings were washed several times with Krebs-Henseleit solution and allowed to equilibrate for 60 min before the experimental protocol began. The concentration-response curves (CRC) for 5'-N-
ethylcarboxamido adenosine (NECA; $10^{-11}$-$10^{-5}$M) and 2-chloro-N (6)
cyclopentyladenosine (CCPA; $10^{-11}$-$10^{-5}$M) were run in parallel in aortic rings from WT
and A₁KO mice. In all cases, drugs were administered to yield the next higher
centration only when the response to the earlier dose reached a steady state. A single
centration of 20-HETE ($10^{-7}$M) was used for all the 20-HETE experiments (Ponnooth
et al., 2012a). In all cases, 20-HETE was administered only when the PE response
reached a steady state. In experiments where the effect of the antagonist was studied, the
drug was added 30 min prior to the contraction of the tissue with PE and was present
throughout the experiments. In all CRC figures, contraction (represented as positive (+)
values) and relaxation (represented as negative (-) values) responses were expressed as a
percentage of increase/decrease in the contraction with respect to PE (alone) in response
to each concentration of agonist used. The concentration used for Penitrem A (Pen A)
was $10^{-6}$M (Borbouse et al., 2009; Asano et al., 2012). For the rest of the drugs, CRCs
were made (NS1619, KCl, PE, ACh, SNP and adenosine agonists) and the sub-maximal
centrations were chosen.

**Immunoblot analysis**

Aortae from WT and A₁KO mice were homogenized with 150 µL radio-immuno
precipitation assay buffer containing (mM) 20 Tris-HCl, 150 NaCl, 1 Na₂EDTA, 1
EGTA, 2.5 sodium pyrophosphate,1 beta-glycerophosphate, and 1 Na₃VO₄; plus 1% NP-
40, 1% sodium deoxycholate, and 1 µg/ml leupeptin. Samples were vortexed and then
centrifuged for 10 min at 13,800 g at 4°C. Protein was measured using the Bradford dye
procedure with bovine serum albumin as a standard (Bio-Rad Laboratories; Hercules,
CA). The protein extract was divided into aliquots and stored at -80°C. Samples (25 µg of
total protein) were loaded on slab gels (10% acrylamide; 1 mm thick), separated by SDS-
PAGE, and transferred to nitrocellulose membranes (Hybond-ECL). Protein transfer was confirmed by visualization of prestained molecular weight markers (Bio-Rad). Membranes were blocked with 5% nonfat dry milk and incubated with primary antibody. A 1:5,000 primary antibody dilution used for BK α and β1 subunits (Alomone laboratories, Israel), while 1:10,000 dilutions were used for secondary antibody and β-actin.

Electrophysiology

WT and A1KO mice aortae were digested in a physiological saline solution containing (mg/ml) 2 collagenase type-II, 1 soybean trypsin inhibitor, 1 bovine serum albumin, and 1 elastase for 30 minutes at 37°C. Single cells were liberated by passing the tissue through the tip of a fire-polished Pasteur pipette. The suspension was passed through a 100 µm nylon mesh and spun for 10 minutes at 10,000g. The pellet was resuspended in low Ca²⁺ physiological saline solution and cells were stored on ice for use within 8 hr. Cells were allowed to attach to glass coverslip, which was then transferred to the recording chamber. Solutions flowed into the recording chamber by gravity at a rate of 2-3 ml/min and the chamber had a volume of 0.2-0.3 ml. BK channel currents were recorded at room temperature from whole-cell patches as described previously (Asano et al., 2010). Bath solution contained (mM) 135 NaCl, 5 KCl, 2 CaCl₂, 1 MgCl₂, 10 glucose, 10 HEPES free acid and 5 Tris base; pH 7.4. Pipette solution contained (mM) 140 KCl, 1 MgCl₂, 1 EGTA and 0.281 CaCl₂ (pCa 7), 10 HEPES, 1 Mg-ATP, 0.1 Na-GTP, and 5 Tris; pH 7.1. pClamp software and an Axopatch 200B amplifier were used (Molecular Devices; Sunnyvale, CA). Currents were low pass filtered at 1 kHz and digitized at 5 kHz.
**Real Time PCR**

The aortic tissues from WT and A_{1}KO were processed for total RNA isolation using the TRI reagent (MRC, Cincinnati, OH) followed by purification of the RNA in aqueous phase and removal of genomic DNA by an RNasy Plus Micro Kit (QIAGEN, Hilden, Germany). This was followed by conversion of 0.5 g of total RNA into cDNA using High Capacity cDNA archive kit (Applied Biosystems, Foster City, CA) in a total volume of 20 µl. Real-time PCR was performed using an ABI PRISM 7300 Detection System (Applied Biosystems) using Taqman Universal Mastermix (Applied Biosystems, Branchburg, NJ) according to the instructions of the manufacturer. The reaction volume (20 µl) consisted of 10 µl of 2X Taqman Universal Mastermix, 4 µl of cDNA, and 1 µl of 20X FAM-labeled Taqman gene expression assay. For the real-time PCR of the concerned genes (Cyp4a10, A_{1}AR, A_{2A}AR, A_{2B}AR and A_{3}AR), the Taqman inventoried assays on-demand gene expression products were purchased from Applied Biosystems (Foster City, CA). 18S rRNA (ribosomal RNA) was used as an endogenous control. The fold difference in expression of target cDNA was determined using the comparative cycle threshold (Ct) method as described earlier (Livak and Schmittgen, 2001).

**Statistics**

Data are expressed as mean ± SEM from n number of mice, because the treatment level (i.e., genotype) is on a per mouse basis. For patch clamp experiments, that means results from all cells from a single mouse aorta were averaged to represent n = 1. Current-voltage relationships were analyzed by two-way repeated measures analysis of variance (ANOVA). This was followed with Bonferroni post hoc test to determine where
differences existed. When only two values were compared (e.g., BK subunit expression) an unpaired t-test was used. $P < 0.05$ was considered significant in all tests.
Results

Total BK current and BK subunit expression in WT and A₁KO mice aortic myocytes

We performed whole-cell patch recordings on aortic smooth muscle cells from WT (Fig. 3.1A) and A₁KO (Fig. 3.1B) mice; we observed no difference in BK current. That is, whole-cell K⁺ current in smooth muscle cells was indistinguishable between WT and A₁KO mice. Currents were normalized to cell capacitance (i.e., current density). The group data are shown in Fig. 3.1C. BK α and β1 proteins were expressed in aortae from both WT and A₁KO mice. BK α and β1 subunit proteins migrated at 100 and 25 kDa, respectively. There were no differences observed in the two protein levels between genotypes (Figs. 3.1D and 3.1E). Thus, the molecular (protein) and functional (current) expression of BK channels was similar in smooth muscle cells from WT and A₁KO mice.

Effect of 20-HETE on BK current in WT and A₁KO mice aortic myocytes

To assess the reported inhibitory effect of 20-HETE on BK channels (Zou et al., 1996; Lange et al., 1997), whole-cell recordings were performed on WT and A₁KO myocytes. We observed a decrease in the BK current in both WT (Fig. 3.2A and 3.2B) and A₁KO (Fig. 3.2D and 3.2E) smooth muscle cells. Mean current density at +100 mV in WT under control conditions was 76.4 ± 12.5 pA/pF (n=4); this was decreased to 51.6 ± 10.3 pA/pF by 20-HETE (Fig. 3.2C). In smooth muscle cells from WT mice, 20-HETE decreased current density 33 ± 7%. Similarly in smooth muscle cells from A₁KO mice, mean current density was 55.6 ± 10.3 pA/pF (n=4) and this was decreased to 41.4 ± 7 pA/pF by 20-HETE (Fig. 3.2F). Thus, in myocytes from A₁KO mice, 20-HETE decreased current density 24 ± 11%.
**Effect of NECA on BK current in WT and A\textsubscript{1}KO mice aortic myocytes**

Whole-cell patch recordings were made in WT and A\textsubscript{1}KO aortic myocytes to determine the effect of NECA on BK current. NECA is a nonselective adenosine receptor agonist and can activate multiple AR subtypes simultaneously. Whole-cell recordings showed prominent BK current in smooth muscle cells from WT and A\textsubscript{1}KO mice. Caffeine (5 mM) was used as a positive control to release Ca\textsuperscript{2+} and increase BK current in both WT and A\textsubscript{1}KO aortic smooth muscle cells (Figs. 3.3E and 3.3F). There was very little change in the BK current in the WT aortic myocytes when stimulated with 10 µM NECA (Fig. 3.3E). In contrast, the BK current in A\textsubscript{1}KO aortic myocytes was significantly increased by 10 µM NECA (Fig.3.3F). The time-dependent increase in BK current with 10 µM NECA in A\textsubscript{1}KO smooth muscle cells was 52 ± 15% (n=7); this was significantly higher than the response to NECA in smooth muscle cells from WT mice (17 ± 3%; n=9; Fig. 3.3G). The disparate responses to NECA in smooth muscle cells from WT and A\textsubscript{1}KO mice suggest that multiple AR subtypes are simultaneously regulating BK channels. Thus, the next experiment was to determine the effect of an A\textsubscript{1}AR-specific agonist on BK channels in smooth muscle cells from WT and A\textsubscript{1}KO mice.

**Effect of CCPA on BK current in WT and A\textsubscript{1}KO mice aortic myocytes**

CCPA (100 nM), an A\textsubscript{1}-selective agonist, decreased BK current in aortic smooth muscle cells from WT mice (Figs. 3.4A and 3.4B). The mean current density at +100 mV in WT was 52.1 ± 5.0 pA/pF (n=4) and decreased with the application of CCPA to 42.8 ± 6.2 pA/pF (Fig. 3.4C). That is, CCPA decreased current density 19 ± 4% in smooth cells from WT mice. In contrast, CCPA had no effect on BK current in smooth muscle cells from A\textsubscript{1}KO mice (Figs. 3.4D and 3.4E). The mean current density at +100 mV in smooth muscle cells from A\textsubscript{1}KO mice was 55.2 ± 7.7 and 54.1 ± 3.9 pA/pF (n=4) in the absence
or presence of 100 nM CCPA, respectively (Fig. 3.4F). That is, current density in the presence of CCPA was 98 ± 7% of control in smooth muscle cells from A$_1$KO mice.

**Effect of PKCα inhibition on BK current in WT and A$_1$KO mice aortic myocytes**

As shown previously (Ponnoth et al., 2012a; Kunduri et al., 2013), PKCα is downstream of A$_1$AR activation, 20-HETE production, and mediates contraction of smooth muscle. We determined if inhibition of PKCα affected regulation of BK current by A$_1$AR activation in smooth muscle cells from WT and A$_1$KO mice. When PKCα was inhibited with Gö6976 (100 nM) in WT smooth muscle cells, subsequent addition of CCPA (100 nM) was no longer able to inhibit current (Figs. 3.5A and 3.5B; compare to Fig. 3.4A-C). In smooth muscle cells from WT mice, mean current density at +100 mV for Gö6976 was 65.9 ± 18.6 pA/pF vs. 64.2 ± 16.6 pA/pF for CCPA + Gö6976 (Fig. 3.5C). That is, current density in the presence of CCPA was 99 ± 3% of control in smooth muscle cells from WT mice treated with Gö6976. There was no effect of CCPA on BK current in A$_1$KO smooth muscle cells whether Gö6976 was present or not (Fig 4.5D-F; note that this is a result similar to that shown in Fig. 3.4D-F). The mean current density at +100 mV in cells from A$_1$KO mice for Gö6976 was 68.5 ± 13.6 pA/pF vs. 66.6 ± 13.2 pA/pF for CCPA + Gö6976 (Fig. 3.5F). That is, current density in the presence of CCPA was 97 ± 1% of control in Gö6976-treated smooth muscle cells from A$_1$KO mice.

**Effect of NS1619 and Penitrem A on adenosine agonists’ induced response:** BK channel opener NS1619 had significantly increased relaxation in A$_1$KO, but had no effect in the WT. We observed that the BK channel inhibitor Pen A had no effect on NECA induced responses in both the WT and A$_1$KO (Fig. 3.5A). However, Pen A increased NECA induced contraction in WT (14.5±1.9%; 10$^{-7}$M) as compared to the A$_1$KO (3.7±4.5%; 10$^{-7}$M). On using the A$_1$ selective agonist, CCPA, we observed no difference
in contraction with the use of Pen A in WT, except at $10^{-5}$M, where higher relaxation was observed with Pen A treatment ($-6.6 \pm 2.8\%$ vs $17 \pm 1.2\%$; Fig. 3.5B).

**Effect of NS1619 and Penitrem A on 20-HETE induced contraction:** 20-HETE induced contraction in both the WT and A$_1$KO, however it was lower in A$_1$KO. The BK channel opener, NS1619 (10µM) decreased the contraction in both the WT ($17.3 \pm 1.2\%$ vs $33.4 \pm 2.9\%$) and A$_1$KO ($5.7 \pm 4.2\%$). NS1619 had further significantly decreased the contraction in the A$_1$KO ($5.7 \pm 4.2\%$) as compared to WT ($17.3 \pm 1.2\%$). However, on using Pen A the contraction was restored to the control levels in both WT ($26.1 \pm 2.5\%$) and A$_1$KO ($16.3 \pm 2.9\%$) (Fig. 3.6).

**mRNA expression of adenosine receptors in WT and A$_1$KO mice:** As expected, A$_1$ receptor expression was observed in WT and not in A$_1$KO. A$_{2A}$AR, A$_{2B}$AR and A$_3$AR were expressed in both WT and A$_1$KO. However, A$_{2A}$AR was the highest in A$_1$KO mice (Fig 3.7).
Figure 3.1: Whole-cell K$^+$ current and BK channel subunit expression is similar in smooth muscle from WT and A$_1$KO mice.

Representative traces of whole-cell K$^+$ current in aortic smooth muscle cells from WT (A) and A$_1$KO mice (B). The voltage template used to elicit the currents in this and subsequent figures is shown below the trace in A; cells were held at -80 mV and stepped from -100 to +100 mV in 20 mV increments. (C) Group data representing whole-cell K$^+$ current in aortic smooth muscle cells from WT (n = 13) and A$_1$KO (n = 20) mice. (D) Representative Western blots from mouse aortae for BK channel subunit expression relative to β-actin (α = 100 kDa; β1 = 25 kDa; β-actin = 42 kDa). (E) Group data for BK α and β1 subunit expression in the aortae of WT (n = 6) and A$_1$KO (n = 6) mice.
**Figure 3.2: Effect of 20-HETE on BK current in WT and A₁KO aortic myocytes:**

Representative current traces are shown under control conditions (A) and with 0.1 µM 20-HETE (B) in a smooth muscle cell from a WT mouse. The voltage template was the same as Fig. 4.1. (C) Group data (n = 5) show the decrease in the BK current by 20-HETE in smooth muscle cells from WT mice. Representative traces are shown under control conditions (D) and with 0.1 µM 20-HETE (E) for a smooth muscle cell from an A₁KO mouse. (F) Group data (n = 5) show the decrease in BK current by 0.1 µM 20-HETE in smooth muscle cells from A₁KO mice. *p<0.05 compared to the respective control.
Figure 3.3: Effect of NECA on BK current in WT and A₁KO aortic myocytes

Representative currents under control conditions (A) and with 10 μM NECA (B) in WT. The voltage template was the same as Fig.4.1. Representative currents under control conditions (C) and with 10 μM NECA (D) in smooth muscle cells from A₁KO mice. Data showing currents vs. time for 10 μM NECA and 5 mM caffeine in smooth muscle cells from WT (E) and in A₁KO (F) mice (blank areas in the time course represent where the protocol was stopped to perform voltage steps) (G) Group data show that NECA increases the BK current more in smooth muscle cells from A₁KO mice compared to WT mice. *p < 0.05 for WT vs. A₁KO; n=7-9.
Figure 3.4: Effect of CCPA on BK current in WT and A$_1$KO aortic myocytes

Representative traces under control conditions (A) and with 0.1 µM CCPA (B) in a smooth muscle cell from a WT mouse. The voltage template was the same as Fig.4.1. (C) Group data representing the decrease in the BK current by CCPA in the WT mice (n = 4). Representative traces show current under control conditions (D) and with 0.1 µM CCPA (E) in a smooth muscle cell from an A$_1$KO mouse. (F) Group data illustrate that there is no effect of CCPA on BK current in smooth muscle cells from A$_1$KO mice. *p<0.05 compared to untreated WT (n=4).
Figure 3.5: Effect of PKCα inhibitor, Gö6976 on BK current in WT and A₁KO aortic myocytes

Representative traces with 0.1 µM Gö6976 (A) and with 0.1 µM Gö6976 + 0.1 µM CCPA (B) in a smooth muscle cell from a WT mouse. The voltage template was the same as Fig.4.1. (C) Group data demonstrate the effect of Gö6976 to prevent CCPA-induced inhibition of BK current in smooth muscle cells from WT mice (n = 4). Representative traces with 0.1 µM Gö6976 (D) and with 0.1 µM Gö6976 + 0.1 µM CCPA (E) in a smooth muscle cell from an A₁KO mouse. (F) Group data representing BK current in Gö6976-treated smooth muscle cells from A₁KO mice (n = 4).
Figure 3.6 Effect of NS1619 on NECA induced relaxation.

Data are expressed as mean ± SEM; **p<0.05 between WT+NS1619 and A1KO+NS1619 and *p<0.05 as compared to A1KO and A1KO+NS1619.
Figure 3.7 Effect of Penitrem A (Pen A) on adenosine agonists’ induced responses: (A) Effect of Penitrem A on NECA induced vascular response

Data are expressed as Mean ±SEM; *p<0.05 as between WT+Pen A and A₁KO + Pen A; n=6-12; (B) Effect of CCPA on Penitrem A induced contraction: Data are expressed as Mean ±SEM; *p<0.05 as between WT+ Pen A and A₁KO + Pen A; *p<0.05 as between WT and WT + Pen A; n=8-12
Figure 3.8 Effect of Penitrem A (BK channel inhibitor; Pen A) and NS1619 (BK channel opener; NS) on CCPA induced contraction.

Values are mean ± SEM; n=6-12; *p<0.05 as compared to WT; #p<0.05 as compared to A1KO; $p<0.05 as compared to WT+NS; **p<0.05 as compared to WT + Pen A
Figure 3.9 Adenosine receptor expression in WT and A₁KO mice aortae

Data are expressed as mean ± SEM (n=10). * p<0.05 compared to the WT.
As shown previously in Fig 3.4, activation of A₁AR by CCPA couples with PLCX via Gx. IP₃, a metabolites of PLC action on phosphatidylinositol 4,5-bisphosphate, releases Ca²⁺ from the sarcoplasmic reticulum (SR) and activates BK channels. AA released by the DAG lipases is metabolized to 20-HETE by Cyp4a, which activates PKC-α. The latter apart from activating ERK1/2, inhibits the BK channels and results in the contraction of the aortic smooth muscle. Activation of BK channels results in hyperpolarization of the smooth muscle membrane which promotes a closure of L-type voltage dependent Ca²⁺ channels that are major players of smooth muscle contraction.
**Discussion**

We tested the hypothesis that activation of A\(_1\)AR inhibits BK channels in aortic smooth muscle via a PKC-dependent mechanism. This hypothesis was based on previous studies indicating: 1) that A\(_1\)AR stimulation is associated with 20-HETE production and activation of PKC (Ponnoth et al., 2012a; Kunduri et al., 2013) and 2) 20-HETE and PKC can inhibit BK channels (Zou et al., 1996; Nowicki et al., 1997; Schubert et al., 1999; Zhou et al., 2009). We performed whole-cell patch clamp and Western blot studies using aortic smooth muscle cells and aortae of WT and A\(_1\)KO mice. Our major findings included: 1) There were no differences in whole-cell K\(^+\) current in aortic smooth muscle cells from WT and A\(_1\)KO mice, nor were there any differences in the expression of pore-forming \(\alpha\) or regulatory \(\beta\)1 subunit proteins. 2) Inhibition of BK current by 20-HETE was similar in aortic smooth muscle cells from WT and A\(_1\)KO mice. 3) NECA, a non-selective AR agonist increased BK current in aortic smooth muscle cells from both WT and A\(_1\)KO mice, but the increase was greater in smooth muscle cells from mice lacking the A\(_1\)AR. 4) CCPA, an A\(_1\)AR-selective agonist, inhibited BK current in smooth muscle cells from WT, but not A\(_1\)KO, mice. 5) Inhibition of PKC\(\alpha\) with Gö6976 abolished the effect of CCPA to inhibit BK current in smooth muscle cells from WT mice. Together, these data lead us to conclude that, in aortic smooth muscle, A\(_1\)AR stimulation inhibits BK channel activity and that this occurs via a mechanism involving PKC\(\alpha\).

BK channels are ubiquitously expressed on the sarcolemma of vascular smooth muscles. BK channels are composed of pore-forming \(\alpha\) subunits with or without regulatory \(\beta\) subunits. The \(\beta\)1 subunit, however, is commonly found in vascular smooth muscles (Nelson and Quayle, 1995; Ledoux et al., 2006; Asano et al., 2010). The \(\alpha\)
subunit is the voltage- and Ca\(^{2+}\)-sensitive pore, while β subunits can modify many characteristics including pharmacology and Ca\(^{2+}\)-sensitivity. We observed no difference in the expression of α or β1 BK subunits (Fig.3.1), suggesting that the channels are equally expressed in aortic smooth muscle cells from WT and A\(_1\)KO mice. Further, there were no differences in BK current magnitude between WT and A\(_1\)KO mice (Fig.3.1). We have previously shown that A\(_1\)AR mediates contraction of smooth muscle via the arachidonic acid metabolite 20-HETE (Ponnoth et al., 2012a; Kunduri et al., 2013). 20-HETE has been shown to inhibit BK channels in rat renal arteriolar smooth muscle cells (Zou et al., 1996; Sun et al., 1999). We have observed similar results in whole-cell patch recordings (Fig. 3.2). That is, 20-HETE decreased BK current similarly in smooth muscle cells from both WT and A\(_1\)KO mice (Fig. 3.2). 20-HETE is a potent vasoconstrictor as shown previously by significant contractions in the aortae of both WT and A\(_1\)KO mice (Ponnoth et al., 2012a; Kunduri et al., 2013). The BK channel opener NS1619 decreased this contraction with significantly higher reduction in the A\(_1\)KO, implying the role of BK channels in the A\(_1\)AR-20-HETE mediated signaling in the vascular response. On using Pen A in WT and A\(_1\)KO, the contraction is restored to their respective control levels. This further underscores that A\(_1\)AR via 20-HETE inhibits BK channel and attenuates relaxation of the smooth muscle cell 20-HETE activates PKC (Lange et al., 1997; Nowicki et al., 1997; Ponnoth et al., 2012a; Kunduri et al., 2013) and PKC may mediate contraction by inhibiting BK channel activity in rat cerebral arteries (Bonev and Nelson, 1996), rabbit portal vein (Kitamura et al., 1992), canine basilar artery(Obara et al., 2002) and rat tail artery (Schubert et al., 1999). This inhibition depends on the sequential phosphorylation of two serines in the C-terminus of the BK α subunit (Zhou et al., 2009). In the present study, when PKC\(\alpha\) was antagonized with Gö6976, CCPA could no longer
inhibit BK channel current (compare Figs. 3.4 and 3.5). This suggests that A1AR signaling through PKCα is negatively coupled to BK channels, perhaps by 20-HETE.

The non-selective adenosine agonist NECA relaxes smooth muscle by acting on A2AR (Rump et al., 1999; Tawfik et al., 2005; Ponnoth et al., 2009), whereas the A1AR-selective agonist CCPA contracts smooth muscle (Ponnoth et al., 2012a; Kunduri et al., 2013). Activation of BK channels by A2AR could lead to membrane potential hyperpolarization and contribute to the relaxation of smooth muscle, whereas inhibition of BK channels by A1AR could cause depolarization and contribute to contraction. We observed that NECA increased BK current significantly in A1KO as compared to the WT (Fig. 3.3). This suggests that the increase in the BK current could be due to the absence of A1 and the non-selective action of NECA on other adenosine receptors (e.g. A2AR) in the A1KO. We have shown that the A2A receptor expression is upregulated in A1KO mice and this might also be a factor in the larger responses to NECA. There is evidence showing that A2AAR, through EETs, activate BK channels (Carroll et al., 2006; Ray and Marshall, 2006). Furthermore, by using the A1 selective agonist CCPA we demonstrated a decrease in BK current in smooth muscle cells from WT mice, but no effect in smooth muscle cells from the A1KO mice. This is the first evidence in the literature showing that A1AR activation inhibits BK current. As the A1AR is known to mediate contraction (Tawfik et al., 2005; Wang et al., 2010; Kunduri et al., 2013), we suggest this may be mediated by inhibition of BK channels. It should be noted, however, that there are reports of A1 activating KATP channels (Dart and Standen, 1993) and linking to nitric oxide-dependent smooth muscle relaxation (Ray and Marshall, 2006). The reasons for such differences are not readily apparent, but may perhaps be attributed to the vascular beds and species.
However, it was surprising to observe in vascular reactivity experiments that the use of BK channel inhibitor, Pen A did not alter the contraction in NECA induced or CCPA induced concentration responses (Fig.3.7A and Fig.3.7B). Previous studies using adenosine or A<sub>2A</sub> receptor agonist in other vessels have produced differing results depending on the tissue and species used. In renal arteries, combination of calcium dependent potassium channel inhibitors, apamin and charybdotoxin didnot have any effect on the A<sub>2A</sub> agonist dilation, but Ibtx at 0.1µmol/L had very little effect (Rump et al., 1999). Similar results were obtained by Carroll MA et al (Carroll et al., 2006) in renal preglomerular vessels. In their study, adenosine mediated dilation via A<sub>2A</sub> through EETs of renal preglomerular vessels was inhibited by 100nM Ibtx. However, there has been no study showing the interaction of adenosine-mediated response via A<sub>1</sub> and BK channels. Though A<sub>1</sub> is primarily know to mediate contraction, there is evidence showing that A<sub>1</sub> mediates vasodilation through K<sub>ATP</sub> channel in the rat aortic endothelium (Ray and Marshall, 2006), in rat diaphragmatic arterioles(Danialou et al., 1997), in the rat skeletal muscle (Bryan and Marshall, 1999). Thus, it is quite possible in the present study that the adenosine in the whole tissue consisting of endothelium and the smooth muscle might cause contraction through the A<sub>1</sub> receptors via inhibition of K<sub>ATP</sub> channels or other K<sup>+</sup> channels. This suggests that there could be another pathway in the whole tissue via which A<sub>1</sub>AR mediates contraction.

Adenosine, via multiple receptor subtypes, contracts and relaxes vascular smooth muscle through several mechanisms, including the regulation of K<sup>+</sup> channels (Dart and Standen, 1993). While adenosine-mediated increases in K<sub>ATP</sub> channel activity are generally well accepted (Sharifi Sanjani et al., 2013), reports regarding the role of BK channels in adenosine-induced smooth muscle relaxation vary widely. In canine coronary
arterioles, vasodilation in response to adenosine is inhibited by iberiotoxin (a very selective BK channel antagonist) (Cabell et al., 1994). Blocking BK channels inhibits vasodilation to 2-chloroadenosine in pig coronary arterioles (Borbouse et al., 2009); however, the role of BK channels in this response is abolished in pigs with metabolic syndrome (Borbouse et al., 2009). Thus, it could be pathology that explains why BK channels play no role in adenosine-induced vasodilation human coronary arterioles (Sato et al., 2005), as they are typically collected from patients with heart disease. Conversely, it may be that BK channels play little, if any role, in adenosine-induced vasodilation, as this has been reported in the majority of studies from pig coronary arterioles (Hein and Kuo, 1999; Hein et al., 2001; Heaps and Bowles, 2002). However, it cannot be ignored that BK channels are reported to contribute to adenosine-induced relaxation or vasodilation of rat cerebral arterioles (Paterno et al., 1996), rabbit renal arteries (Rump et al., 1999), rat aortas (Ray and Marshall, 2006), and rat preglomerular microvessels (Carroll et al., 2006). Further, adenosine increases a Ca$^{2+}$-dependent K$^{+}$ current in smooth muscle cells from the rat mesenteric artery that may be mediated by BK channels (Li and Cheung, 2000). At present, there is little consensus regarding the role of BK channels in adenosine-induced smooth muscle relaxation and very little data directly addressing whether adenosine increases BK current in smooth muscle cells isolated from those same arteries or arterioles. Thus, from our data, we conclude that A$_1$AR signaling inhibits BK channels via 20-HETE and PKC$\alpha$. However, in the whole tissue consisting of the endothelium and smooth muscle, there could be other potassium channels or ion channels playing role in mediating contraction through A$_1$AR and this needs to be further explored to have a complete understanding of the signaling mechanism involved in A$_1$AR mediated contraction.
**References**


CHAPTER FOUR: CONCLUSIONS

The work presented in this dissertation establishes a relationship between $A_1$-AR and Cyp4a. We have shown that $A_1$-AR mediated contraction of the smooth muscle involves Cyp4a product, 20-HETE via PKC-$\alpha$ and ERK 1/2 dependent pathway. Furthermore, this effect on the smooth muscle occurs by the inhibition of BK channel in a PKC-$\alpha$ dependent manner.

The first evidence for an interaction between $A_1$-AR and Cyp4a is the effect of the Cyp4a inhibitor (HET0016) on adenosine agonists’ (NECA and CCPA) elicited vascular responses in WT and $A_1$KO mice aortae. Due to the similar responses to adenosine agonists in the mice mesenteric arteries and aortae, we used aortae for these studies (Teng et al., 2011). Pharmacological inhibition of Cyp4a dramatically reduced the contraction responses induced by NECA, in both the WT and the $A_1$KO mice aortae and a significantly higher relaxation was observed in NECA-induced aortic responses in $A_1$KO (Fig. 2.2A).

These findings were further confirmed when Cyp4a inhibitor (HET0016) attenuated the vasoconstriction evoked by the $A_1$ agonist, CCPA in the WT with no significant difference in the treated and untreated $A_1$KO tissues (Fig.2.2B). This coupled with lower Cyp4a protein levels in $A_1$KO mice aortae (Fig. 2.1A) as compared to WT suggest a role for Cyp4a in adenosine-elicited contraction of the smooth muscle through the $A_1$AR.

20-HETE is known to be a potent vasoconstrictor in several vascular beds. When administered exogenously in our experiments, it elicited contraction responses in both WT and $A_1$KO at very low concentrations of $10^{-11}$ M (Fig 2.3A-D). Our data show that
20-HETE vascular responses in aortae and mesenteric arteries are lower in A\textsubscript{1}KO compared to the WT (Fig.2.3E). Moreover, the \textit{Cyp4a} functional activity evaluated by the 20-HETE formation rates in the aortic microsomes was found to be lower in the A\textsubscript{1}KO as compared to the WT mice (Fig 2.4). This further underscores the role of \textit{Cyp4a} in A\textsubscript{1}AR mediated vasoconstriction.

There is a dynamic interplay between the metabolites of the two pathways of \textit{Cyp450} enzymes, EETs and 20-HETEs, in the modulation of vascular homeostasis. As \textit{Cyp4a} and \textit{Cyp2c} products have functionally antagonistic effects, we investigated if \textit{Cyp2c29} has any relationship to the A\textsubscript{1}AR mediated vascular responses. We observed that \textit{Cyp2c29} protein levels were significantly up-regulated in A\textsubscript{1}KO mice as compared to the WT (Fig 2.5A). Since we have seen an up-regulation of \textit{Cyp2c29} in A\textsubscript{1}KO compared to WT mice, it is quite possible that relaxation observed in A\textsubscript{1}KO mice by \textit{Cyp4a} inhibition is due to \textit{Cyp2c29} product EETs and due to the inhibition of \textit{Cyp4a} that limits the production of 20-HETE. This observation was confirmed by the enhanced CCPA mediated vasoconstriction in the presence of the Cyp-epoxygenase inhibitor, MSPPOH (Fig.2.5B). We have shown earlier that \textit{Cyp4a} protein levels are up regulated with MSPPOH treatment (Nayeem et al., 2008). In the WT, although Cyp-epoxygenases were inhibited, a higher contraction observed with MSPPOH treatment is due to higher levels of \textit{Cyp4a} and in the A\textsubscript{1}KO, the higher vascular response is due to inhibition of the Cyp-epoxygenases. Thus, the down-regulation of \textit{Cyp4a} and an up-regulation of \textit{Cyp2c29} protein levels promote the relaxation observed in the A\textsubscript{1}KO littermates. This inverse relationship between \textit{Cyp4a} and \textit{Cyp2c} is consistent with findings from other investigators in rat afferent arterioles and preglomerular arterioles (Hercule and Oyekan, 2000; Imig et al., 2000).
The next aim was to determine the signaling mechanism by which adenosine A\textsubscript{1} receptor-20-HETE pathway mediates contraction of the smooth muscle downstream. Exogenous administration of 20-HETE produced similar higher contraction response in WT than the A\textsubscript{1}KO, both in the mice aortae and mesenteric arteries (Fig.2.3), thus, suggesting that the signaling proteins downstream of 20-HETE are essential in \textit{Cyp4a} modulation of A\textsubscript{1}AR mediated vasoconstriction. The use of a specific PKC-\textalpha blocker attenuated the 20-HETE mediated vasoconstrictor response in WT and A\textsubscript{1}KO mice aortae (Fig.2.6A-C). Similarly, pharmacological inhibition of ERK1/2 with PD98059 decreased the 20-HETE-elicited contraction in the WT and almost abolished the contractile tone in the A\textsubscript{1}KO (Fig2.7A-C). However, the greater blockade of the vasoconstrictor responses with ERK inhibitor than with the PKC-\textalpha inhibitor implies that MAPK pathway activation may involve several kinases like PKA, PKC, rho kinases or Ras activation or a cross talk between the different tyrosine kinase receptors. These data substantiate the role of PKC-\textalpha and ERK1/2 in A\textsubscript{1}AR mediated vasoconstriction through 20-HETE (Fig. 2.6 and 2.7).

Electrophysiological studies have revealed that BK channels negatively regulate the A\textsubscript{1}AR–20-HETE mediated aortic smooth muscle contraction. Our data showed that the total BK current and BK protein expression was unchanged in both WT and A\textsubscript{1}KO aortic smooth muscle cells (Fig.3.1). 20-HETE decreased the BK current in our studies as reported by several groups in different vascular beds and species (Fig.3.2). 20-HETE is a potent vasoconstrictor as shown by the significant contraction in WT and A\textsubscript{1}KO (Ponnoth et al., 2012a; Kunduri et al., 2013). The BK channel opener NS1619 decreased this contraction with significantly higher reduction in the A\textsubscript{1}KO, implying the role of BK channels in the A\textsubscript{1}AR-20-HETE mediated signaling in the vascular response. On using Pen A in WT and A\textsubscript{1}KO, the contraction is restored to their respective control
levels. This further underscores that $A_1$AR via 20-HETE inhibits BK channel and attenuates relaxation of the smooth muscle cell (Fig 3.8)

Adenosine receptor stimulation with NECA increased the BK current in $A_1$KO and not in WT (Fig.3.3). This suggests that $A_1$AR negatively regulates the BK channel and the lack of it removes the inhibition. As cited previously, $A_2$AR is known to couple with EETs and BK channels in mediating relaxation. We have shown in this dissertation that $A_2$AR is up-regulated in $A_1$KO mice aortae (Fig.3.9). It is quite plausible that the increase in BK current could also be contributed by $A_2$R receptors via EETs. Use of the $A_1$ selective agonist CCPA decreased the BK current in WT with no effect on the $A_1$KO aortic smooth muscle cells (Fig.3.4).

However, it was surprising to observe in vascular reactivity experiments that the use of BK channel inhibitor, Pen A did not alter the contraction in NECA induced or CCPA induced concentration responses (Fig.3.7). Previous studies using adenosine or $A_2$A receptor agonist in other vessels have produced differing results depending on the tissue and species used. In renal arteries, combination of calcium dependent potassium channel inhibitors, apamin and charybdotoxin didnot have any effect on the $A_2$A agonist dilation, but Ibx at 0.1µmol/L had very little effect (Rump et al., 1999). Similar results were obtain ed by Carroll MA et al (Carroll et al., 2006) in renal preglomerular vessels. In their study, adenosine mediated dilation via $A_2$A through EETs of renal preglomerular vessels was inhibited by 100nM Ibx. However, there has been no study showing the interaction of adenosine-mediated response via $A_1$ and BK channels. Though $A_1$ is primarily know to mediate contraction, there is evidence showing that $A_1$ mediates vasodilation through $K_{ATP}$ channel in the rat aortic endothelium (Ray and Marshall, 2006), in rat diaphragmatic arterioles(Danielou et al., 1997), in the rat skeletal muscle (Bryan
and Marshall, 1999). Thus, it is quite possible in the present study that the adenosine in the whole tissue consisting of endothelium and the smooth muscle might cause contraction through the A₁ receptors via inhibition of $K_{ATP}$ channels or other $K^+$ channels. This suggests that there could be another pathway in the whole tissue via which A₁AR mediates contraction.

Thus, in summary we conclude that adenosine A₁ receptor by coupling with 20-HETE and PKC-α limits adenosine-mediated relaxation in the aortic smooth muscle cells by inhibiting BK channels. However, in the whole tissue consisting of the endothelium and smooth muscle, there could be other potassium channels or ion channels playing role in mediating contraction through A₁AR and this needs to be further explored to have a complete understanding of the signaling mechanism involved in A₁AR mediated contraction.
Figure 4.1: Schematic showing the events leading from activation of $A_1$AR coupled to Cyp4a product, 20-HETE and mediating contraction through PKC-$\alpha$ and p-ERK1/2 and BK channels
Figure 4.2: Schematic showing the events in the absence of A₁AR. NECA possibly activates A₂AR, leading to activation of Cyp-epoxygenases, which produce EETs and activate K_{ATP} channels (Nayeem et al., 2008; Ponnoth et al., 2012a; Ponnoth et al., 2012b); EETs diffuse out of the endothelial cell and are also known to activate BK channels in the smooth muscle.
Figure 4.3: Effect of Glibenclamide (Glib; 10μM) on CCPA induced contraction.

Data are expressed Mean ± SEM; *p<0.05 between WT and WT+Glib and **p<0.05 between A₁KO and A₁KO+Glib; n=6
Future Directions

The next step for this project would be to determine the ion channels in the endothelium that could be involved in the regulation of the vascular tone by A1AR and Cyp450 metabolites. Our preliminary vascular reactivity experiments showed that K\textsubscript{ATP} inhibitor, Glibenclamide (Glib) significantly increased the CCPA induced contraction in WT as well as A1KO (Fig.4.3). This suggests that Glib- sensitive K\textsubscript{ATP} channels contribute to adenosine-mediated relaxation and inhibition of these channels contribute to the A1-mediated contraction.

K\textsubscript{ATP} channels are octameric complexes composed of four SUR and four Kir subunits. They are found in the vascular smooth muscle of both resistance and conduit arteries (Quayle et al., 1997). Several studies have shown that A1AR mimics adenosine effects by coupling with K\textsubscript{ATP} in the rat aortic endothelium and causing release of nitric oxide (NO) (Ray and Marshall, 2006) in pig coronary arterioles smooth muscle cells (Dart and Standen, 1993), rat diaphragmatic arterioles (Danialou et al., 1997) and in the rat skeletal muscle (Bryan and Marshall, 1999). Our lab has shown previously that A1AR is up-regulated in A2\textsubscript{A}KO mice aortae (Ponnoth et al., 2012b) and Glib causes higher contraction to NECA in A2\textsubscript{A}KO (Ponnoth et al., 2012b). This meshes well with our preliminary data suggesting that inhibition of the K\textsubscript{ATP} channel is involved in the A1AR regulation of vascular tone. Furthermore, our lab has shown that the endothelial K\textsubscript{ATP} channels are activated by the A2\textsubscript{A}AR-Cyp-epoxygenases pathway in the mouse aorta (Ponnoth et al., 2012a). Given this evidence, we speculate that in the endothelium, the activation of A1AR causes inhibition of K\textsubscript{ATP} channels and this signal is transduced to smooth muscle resulting in its contraction.
However, more experiments such as vascular reactivity studies to confirm the involvement of endothelial $K_{\text{ATP}}$ channels in $A_1$AR mediated responses are needed. Electrophysiological experiments can be done to further confirm the findings using the $A_1$KO and WT aortic endothelial cells. However, the signaling and the role of Cyp450 metabolites pathway in mediating this vascular function is unknown and needs to be studied. Since both the Cyp450 metabolites and adenosine play a role in the preservation of a normal endothelial functioning, understanding the relationship between them will provide a deeper insight of the factors underlying endothelial dysfunction, a major contributor to several cardiovascular diseases.

The role of Cyp4a metabolite, 20-HETE in blood pressure regulation is well documented, and 20-HETE functions as a pro-hypertensive or as an antihypertensive eicosanoid depending on its expression site. In the renal tubules, it functions as an antihypertensive by inhibiting the Na$^+$ transport and increasing Na$^+$ loss. In contrast, in the peripheral vessels it functions as a pro-hypertensive, by increasing the vascular tone, thereby increasing the peripheral vascular resistance and the arterial pressure (Williams et al., 2010). There is overwhelming evidence that mutations in $Cyp4a11$ and $Cyp4f2$ lead to the development of hypertension in human population studies. Moreover, prolonged hypertension is a harbinger for atrial fibrillation, left ventricular hypertrophy, myocardial infarction, congestive heart failure leading to end stage renal disease and stroke (Kraja et al.; Dobbelsteyn et al., 2001).

There are conflicting reports of involvement of $A_1$AR in blood pressure regulation. Brown et al, 2001 and Wang et al, 2010 (Brown et al., 2001; Wang et al., 2010) have shown that blood pressure levels are elevated in A1KO mice, whereas, Sun et al, 2001 and Schweda et al, 2005 (Sun et al., 2001; Schweda et al., 2005) have shown no
difference in blood pressure between the WT and A1KO mice. Although the role of A1AR in regulation of heart rate and cardio-protective action after an ischemic insult is well-documented (Jacobson and Gao, 2006), its role in blood pressure regulation remains ambiguous.

Thus, the findings of this dissertation, which shed some light on the relationship between A1AR and 20-HETE, can serve as the basis for further exploration of the role of A1AR in blood pressure.
References


Dobbelsteyn CJ, Joffres MR, MacLean DR and Flowerdew G (2001) A comparative evaluation of waist circumference, waist-to-hip ratio and body mass index as


Hercule HC and Oyekan AO (2000) Cytochrome P450 omega/omega-1 hydroxylase-derived eicosanoids contribute to endothelin(A) and endothelin(B) receptor-mediated vasoconstriction to endothelin-1 in the rat preglomerular arteriole. *J Pharmacol Exp Ther* **292**:1153-1160.


Tracey WR, Magee W, Masamune H, Oleynek JJ and Hill RJ (1998) Selective activation of adenosine A3 receptors with N6-(3-chlorobenzyl)-5'-N-


PUBLICATIONS and ABSTRACTS

Papers:
- **Kunduri SS**, Dick GM, Nayeem MA, Mustafa SJ Adenosine A₁ receptors regulate BK channels through a PKCα-dependent mechanism in mouse aortic smooth muscle (under review at AJP-Heart and Circulation)
- **Kunduri SS**, Mustafa SJ, Ponnoth DS, Tilley S, Dick GM, Nayeem MA Adenosine A₁ receptors link to smooth muscle contraction via CYP4a, PKC-α and ERK1/2 pathway (J Cardiovasc Pharmacol. 2013 Mar 20. [Epub ahead of print])

Abstracts:
- **Kunduri SS**, Nayeem MA, Ponnoth DS, Tilley S, Mustafa SJ Role of L-type voltage gated calcium and large conductance potassium channels in A₁AR-Cyp450. Experimental Biology 2012
- **Kunduri SS**, Nayeem MA, Ponnoth DS, Tilley S, Schnerrmann JS, Mustafa SJ ω-hydroxylase mediates adenosine A₁ receptor mediated vasoconstriction. Experimental Biology 2011
- **Kunduri SS**, Falck JR, Schnerrmann J, Nayeem MA and Mustafa SJ Exaggerated vasoconstriction depends on ω-hydroxyylase through adenosine A₁ receptor (AR) in A₁ WT compared to A₁ KO mouse aorta. Experimental Biology 2010
APPENDIX A

This section provides preliminary data to determine the effect of adenosine agonists in WT and A₁KO mice aortae.

Fig. A.1. Preliminary experiments were carried out to determine the effect of NECA in WT (C-57/BL6) and A₁KO mice. NECA induced relaxation in both WT and A₁KO. However, NECA induced relaxation was significantly higher in A₁KO mice due to ablation of A₁AR gene (n=8-12). Data are expressed as Mean± SEM, *p<0.05 as compared to WT; (n=8-12).

NECA CONCENTRATION RESPONSE CURVE IN WT AND A₁KO MICE
Fig. A.2. Preliminary experiments were carried out to determine the effect of CCPA in WT (C-57/BL6) and A1KO mice. CCPA induced contraction in WT and the lack of A1AR gene results in relaxation in A1KO. Data are expressed as Mean± SEM, *p<0.05 as compared to WT; (n=8-12).
Fig. A.3. Ach induced relaxation in WT and A1KO mice aortae and mesenteric arteries. There was no difference in the acetylcholine induced responses in WT and A1KO mice in both aortae and mesenteric arteries. Data are expressed as Mean± SEM, *p<0.05 as compared to WT; (n=6-12).

ACETYLCHOLINE INDUCED RELAXATION
APPENDIX B

This section provides preliminary data to determine the involvement of L-type Ca\(^{2+}\) channels in the A\(_1\)AR and 20-HETE mediated contraction using WT and A\(_1\)KO mice aortae. Also, the effect of Iberiotoxin on CCPA induced contraction. The results observed were similar to the effect of Penitrem A.
Fig.B.1. To determine the involvement of L-VDCC in A₁AR mediated contraction, we assessed the effect of Nifedipine on CCPA induced contraction. Nifedipine (Nif) inhibited CCPA-induced contraction and resulted in relaxation similar to control A₁KO. Nif did not effect CCPA induced contraction in A₁KO mice aortae. Data are expressed as Mean± SEM, *p<0.05 as compared to WT; (n=8-12)

**EFFECT OF NIFEDIPINE (Nif) ON CCPA- INDUCED CONTRACTION**
Fig.B.2. To determine the involvement of L-VDCC in 20-HETE mediated contraction, we assessed the effect of Nifedipine on 20-HETE induced contraction. Nifedipine (Nif) attenuated 20-HETE-induced contraction in both WT and A\textsubscript{1}KO. However, the decrease in contraction was higher in A\textsubscript{1}KO by Nif. *p<0.05 as compared to WT and #p<0.05 as compared to A\textsubscript{1}KO.

EFFECT OF NIFEDIPINE ON 20-HETE INDUCED CONTRACTION
Fig. B.3. Iberiotoxin (Ibtx; BK channel inhibitor) had no effect on CCPA induced contraction in WT. Data are expressed as Mean ± SEM; n=6
This section provides preliminary data to determine the effect of adenosine agonists in WT and Cyp2c29KO mice aortae. It also shows ACh response of WT and Cyp2c29KO mice aortae and mesenteric arteries. These mice were obtained from NIEHS to further explore the role of adenosine receptors and CYP metabolites. However, the results weren’t promising.
Fig.C.1. NECA induced concentration response in WT and Cyp2c29KO. Data are expressed as Mean ± SEM, n=6

NECA CONCENTRATION RESPONSE IN Cyp2c29KO MICE
Fig. C.2. CCPA induced concentration response in WT and Cyp2c29KO. Data are expressed as Mean ± SEM, n=6.
Fig.C.3. CGS induced concentration response in WT and Cyp2c29KO. Data are expressed as Mean ± SEM, n=6.

CGS CONCENTRATION CURVE IN Cyp2c29KO MICE
Fig.C.4. ACh induced relaxation was no different in WT and Cyp2c29Ko mice. Data are expressed as mean ± SEM; n=8-10
CURRICULUM VITAE

EDUCATION

2013 (August)  PhD in Physiology and Pharmacology, West Virginia University, Morgantown
2006  M.S in Biomedical Sciences, University of Delhi, Delhi, India
2004  B.S in Zoology (Honors), University of Delhi, Delhi, India

TECHNICAL SKILLS

Animal Work (breeding, weaning and maintaining mice colonies), Organ bath, Patch Clamp, Cell Culture, Genotyping, Electroporation, Immunoprecipitation, Protein Extraction and Purification, Protein Labeling, Western Blots, DNA Extraction and Purification, DNA Labeling, PCR, RT-PCR, Bacterial Work (Transformation, Competent Cells)

RESEARCH EXPERIENCE

08/08-Present  Doctoral Candidate, Center for Cardiovascular and Respiratory Sciences, West Virginia University, Morgantown, West Virginia
05/06-05/07  Graduate Research Assistant, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, West Virginia
05/05-05/07  Summer Research Internship, Dr. B.R. Ambedkar Center for Biomedical Sciences, Delhi, India
01/06-06/06  Research Internship, Dr. B.R. Ambedkar Center for Biomedical Sciences, Delhi, India

AWARDS and HONORS

2013  2nd place, Basic Science group poster competition, E.J.Van Lier Research Day,, WVU
2012  School of Pharmacy Doctoral Student Travel Award, WVU
2012  3rd place, Basic Science poster presentation, 20th American Heart Association Fellows Meeting
2011  2nd place, Basic Science group poster competition, E. J. Van Liere Research Day, WVU
2010  American Radiolabeled Chemicals Junior Scientist Award in Pharmacology, Experimental Biology Meeting, 2010
2010  Graduate Research and Education Doctoral Student Travel Award, WVU
2010  School of Pharmacy Doctoral Student Travel Award, WVU
2004  Council of Scientific & Industrial Research – Catch them young scholarship for academic brilliance in post-graduation, Delhi, India
2005  Council of Scientific & Industrial Research – Catch them young scholarship for academic brilliance in post-graduation, Delhi, India
1998  Top 0.1% in Mathematics, Central Board of Secondary Education

WORKSHOPS:

2011  Grant Writing Seminar workshop
2011 Professional Skills development: poster and oral presentations workshop

**TEACHING EXPERIENCE:**

- 6/12-12/12 Instructor, Cell Methods Course
- 9/11- 4/12 Facilitator, Medical Pharmacology

**PUBLICATIONS:**

Papers:
- **Kunduri SS,** Dick GM, Nayeem MA, Mustafa SJ Adenosine A1 receptors regulate BK channels through a PKCα-dependent mechanism in mouse aortic smooth muscle (*in Press at Physiological Reports*)
- **Kunduri SS,** Mustafa SJ, Ponnoth DS, Tilley S, Dick GM, Nayeem MA Adenosine A1 receptors link to smooth muscle contraction via CYP4a, PKC-α and ERK1/2 pathway (*J Cardiovasc Pharmacol.* 2013 Mar 20. [Epub ahead of print])

Abstracts:
- **Kunduri SS,** Dick GM, Nayeem MA, Mustafa SJ Adenosine A1 receptor signaling inhibits BK channels. *Experimental Biology,* 2013
- **Kunduri SS,** Falck JR, Schnermann J, Nayeem MA and Mustafa SJ Exaggerated vasoconstriction depends on ω-hydroxylase through adenosine A1 receptor (AR) in A1 WT compared to A1 KO mouse aorta. *Experimental Biology* 2010

**CONFERENCES**

- 2012 American Heart Association Fellows Meeting, Pittsburgh
- 2012 Experimental Biology Meeting, San Diego
- 2011 Experimental Biology Meeting, Washington D.C
- 2010 Experimental Biology Meeting, Anaheim